¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/20 ¤U¤È 12:50:30
²Ä 3683 ½g¦^À³
|
JCY ¤j ,
¬üªÑ¤½¥¬¸Ñª¼¼Æ¾Ú¬O§_¦b½L«á? ¤@¯ë¬O.
2021¦~¤¸¤ë11¤é, DMC§åã¤F¦b¬ã¨sªº«e¤TÓ¶¤¦Cªº¤£©ú¼Æ¾Ú¤§«e¥H³Ì°ª¾¯¶q¶}©ñÂX±iÁ{§Éªº«Øij
¦Ü¤Ö°µ§¹¥|¶gªvÀøÆ[¹î(Ó¤H§PÂ_)
ASLAN004 AD 1b Á{§É¥Dn«ü¼Ð
Primary Outcome Measures : To assess the safety and tolerability of multiple ascending doses of ASLAN004: Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to 12 weeks safety follow up ] Incidence of treatment-emergent adverse events (TEAEs) reported from the administration of study drug on Day 1 until the completion of the study. ¥Dnµ²ªG«ü¼Ð¡G
µû¦ô¦h¦¸»¼¼W¾¯¶qªºASLAN004ªº¦w¥þ©Ê©M@¨ü©Ê¡GªvÀøºò«æ¤£¨}¨Æ¥ó¡]TEAE¡^ªºµo¥Í²v[®É¶¡½d³ò¡G°ò½u¦Ü12¶g¦w¥þÀH³X] ±q²Ä1¤Ñ¶}©lªA¥Î¬ã¨sÃĪ«ª½¦Ü§¹¦¨¬ã¨s¬°¤î¡A§¡³ø§i¤FªvÀøºò«æ¤£¨}¨Æ¥ó¡]TEAE¡^ªºµo¥Í²v¡C
¬Æ¥L9¶µ¦¸n«ü¼Ð:®É¶¡°ò½u¦Ü8¶g&¤@¶µ12¶g
¬GÓ¤H§PÂ_¤¸¤ë11¤é+8¶g ¥i¸Ñª¼, ¬O§_n¥[¤@Ӥ몺¸ê®Æ¦¬¶°/§PÂ_®É¶¡? ¤£ª¾
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJCY10146705 |
µoªí®É¶¡:2021/2/20 ¤U¤È 12:32:02
²Ä 3682 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j ¤Ñ©R¤j¦ôp3¤ë11¤é-15¤é¥i§¹¦¨12¶gªºsafety follow up ¼Æ¾Ú¤ÀªR¬O·|µ¥safety follow up§¹¦¨«á¤~¶}©l¶i¦æ¶Ü? ·PıÁ{§É¸ÕÅ窺¼Æ¾Ú¤ÀªR³£n¦A¤@¨âÓ¤ë
¥t¥~ÁÙ¦³Ó°ÝÃD·Q½Ð±Ð ¥xªÑªº¥Í§ÞªÑ³£¬O½L«á¤½¥¬¸Ñª¼µ²ªG ¬üªÑ¤]¬O¶Ü? ¤£¾å±o»Ý¤£»Ý¦b¬üªÑ½L¤¤µ¥«Ý¸Ñª¼¤½¥¬? ·PÁ¤ѩR¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/2/20 ¤W¤È 09:26:35
²Ä 3681 ½g¦^À³
|
ÁÂÁ«Ӱ¶¤jªºÀ°¦£»¡©ú¡A¥¼¨Ó³Ì§Æ±æ¦Ñ·à´Â¤Ñ©R¤jªº³W¹º¨«¡A²¦³º¦Ñ·à±q¦b¥x¤W¥««á´N¬O¤@¸ô©¹ªF«n¤è¨«¡A¨«¨ì²{¦b¡A©³¤]¥´±o°÷§¹¾ã¡A¤]¨«±o°÷¤[¡A¥Ø«eÀ³¸Ó¬O¶}©l°_º¦¤F~²Ä¤@ªiªº§Ç¦± |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/20 ¤W¤È 08:55:54
²Ä 3680 ½g¦^À³
|
预´ÁÀ禬
ASLAN001¤¹DÀù3-4»õ¬ü¤¸(¤wÂk¹s) ASLAN004 60-120»õ¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/20 ¤W¤È 08:40:42
²Ä 3679 ½g¦^À³
|
©t¨à¤j§ïÅܾԳN¬O¥²µMªº ¦bGÀùÁx¹DÀù±µ³s¥¢±Ñ®É §Ú¤]¦n·Q¯à°÷²æ¤â ¦ý²{¦b¤£¦P¤F ©¼¤@®É¦¹¤@®É¡A²{¦bªº004·Pı¬O«Ü¦³¾÷·|ªº (¤§«eGÀùÁx¹DÀù«eªÑ»ù¨Ã¤£¹³³o¦¸¦p¦¹±j¶Õ) §Æ±æ³o¦¸004¼Æ¾Ú¯à°÷´¬Ü¦R®ð |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/20 ¤W¤È 06:43:42
²Ä 3678 ½g¦^À³
|
°O±o©t¨àÃĤj¤§«e¦³po¤å ¦pªG¦^¨ì¹L¥h30¤¸®É·|°±·l ¥X³õ¡A¤£¹L²´¬Ý¨¯¤Ú³o®ð¶Õ ¡A¤£ª¾¹D¬O¤£¬O¦Ò¼{§ïÅܤ@¤U ¾Ô³N |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/20 ¤W¤È 06:31:20
²Ä 3677 ½g¦^À³
|
±j¶ÕªÑ´N¬O³o¼Ë¡A½æ¦¤Fºl¤ß¤z¡A©M®M¨c¤F¤@¼Ë µhW¡A´Á«Ý¥L©Ô¦^¡A¥L°¾°¾¤Ñ¤Ñº¦µ¹§A¬Ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/20 ¤W¤È 03:52:14
²Ä 3676 ½g¦^À³
|
Primary Outcome Measures : To assess the safety and tolerability of multiple ascending doses of ASLAN004: Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to 12 weeks safety follow up ] Incidence of treatment-emergent adverse events (TEAEs) reported from the administration of study drug on Day 1 until the completion of the study.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
clinicaltrials.gov/ct2/show/NCT04090229
ASLAN004 ¤¤-««×Âùª¼·§©À©ÊÁ{§Éªº¥Dn«ü¼Ð
»Ý12¶gªº随³X¡C
¦ôp3¤ë11¤é¤@15¤é¡A¥i¹F12¶g¡C ¸Ñª¼®É¶¡约¦b¦¹¶¥¬q¡C
ªÑ»ù¥i¯à¦A©Ô°ª¨ì8¬ü¤¸ ¸Ñª¼·í¤Ñ¡A¤@¤Ñ©Ô¨ì16¬ü¤¸ 5¤ë¤¤¨ì¤»¤ë¤½¥¬©µ¦ù©ÊÁ{§É资®Æ ªÑ»ù©Ô¤W21¬ü¤¸¡A§¹¦¨1.5»õ¬ü¤¸ªº¼W资¡C
¥H¤W¦¨¥\¶Òªº1.5»õ¬ü¤¸ªº¥i¯à¸ô®|¤§¤@¡C
Y¦¨¥\¡A¤U¦¸©ú¦~©³°µ§¹2b¡A ¶Ò3´Á5»õ¬ü¤¸资ª÷¡A¥ç¬O¥²n¤§Á|¡C
40¬ü¤¸x13,500¤dªÑADR(¥i¶ÒªÑ¼Æ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/2/20 ¤W¤È 12:37:56
²Ä 3675 ½g¦^À³
|
©ú¤Ñ¤j¡A§Æ±æ±zªº·Qªk¤£·|¦¨¯u~¤@¸ôª½¤W¤~¬O¥¿¹D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/2/19 ¤U¤È 04:49:48
²Ä 3674 ½g¦^À³
|
¤µ¦~¥H¨ÓASLN¤w¸gº¦´T¶W¹L100%,ÄÝ©ó¶W±j¶ÕªÑ²¼,¦ýº¦¦h¤@©w·|¦^¦R©Ò¥Hµu½u¦^¶^¤£¥iÁקK,¥¼¨Ó´XÓ¥æ©ö¤é¹w¦ô±N¦^¶^3¦¨,¬ù2.8»ù¦ì°Ï¶¡¾ã²z,©Ò¥H2.8³oÓ»ù¦ì¦pªG¦³¨Ó¨ì¥i¥H«ùÄò¥[½X!¦pªG«Dª¼¼Æ¾Úµo§GÁÙ¤£¿ù·|¬O¥t¥~¤@¬qötº¦ªº¶}©l ! ¹w´ú¤µ¤ÑÀ³¸Ó·|3.3~3.4»ù¦ì ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/19 ¤U¤È 03:01:30
²Ä 3673 ½g¦^À³
|
³sÄòº¦À³¸Ó¤£¬OGRAHAMªºì¦] ¤ñ¸û¹³¬Oªì´Á¼Æ¾Ú§Y±N¤½¥¬¡A¦Ó¤½¥q¤S¦³¶Ò¤j¸êª÷·s»D Åý¥«³õı±o¤½¥q¥¼¨Ó¼ÖÆ[¥¿¦V§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/2/19 ¤U¤È 01:02:45
²Ä 3672 ½g¦^À³
|
½Ð°Ý§äGraham³Õ¤h¨Ó ¬O¤£¬O¥Nªí¨È狮ASLAN004n¦Û°µ¤T´Á¡A¦Û¦æ¾P°â
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/2/18 ¤U¤È 11:44:51
²Ä 3671 ½g¦^À³
|
³o¥y¤~¬O«ÂI... ÀHµÛ§Ú̱µªñ¤µ¦~ASLAN004©MASLAN003Á{§É¶}µoªº«n¨½µ{¸O¡A¥L¦b§K¬Ì¾Ç©Mª¢¯g¾Ç¤è±ªº¥þ²y±M·~ª¾ÃÑ¥H¤Î¾Ô²¤«ü¾É±N¹ï§Ú̪º¹Î¶¤¨ã¦³«n»ùÈ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/2/18 ¤U¤È 11:03:26
²Ä 3670 ½g¦^À³
|
©Ò¥H «e´X¤Ñªº³sÄòº¦ ¬O¦]¬° DR NEIL GRAHAM ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/18 ¤U¤È 09:10:44
²Ä 3669 ½g¦^À³
|
¨È·à¤¤°êªº¸³¨ÆÃã¥ô
www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=46a22363-a900-4027-a309-c448a14b6a44 ¸³¨ÆAlnair Investment ªk¤H¸³¨Æ¥Nªí¤H¡GJun Wu§dÂ@ 7.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¤§¤½¥q¦WºÙ¤Î¾°È: (1). ©M®|ÂåÃĬì§Þ(¤W®ü)¦³¤½¥q¸³¨Æ (2). ¤W®ü¿DµØ¥ú¹q¿sÃ観¤½¥q¸³¨Æ (3). ¤W®ü¦nÂå³q°·±d«H®§«t¸ß¦³¤½¥q¸³¨Æ (4). ¤W®üÁpÆk¥Íª«¬ì§Þ¦³¤½¥q¸³¨Æ (5). ¤W®ü¿Óµ®«H®§¬ì§Þ¦³¤½¥q¸³¨Æ (6). ¤W®üÆ_¥@°é¶³°·±d¬ì§Þµo®i¦³¤½¥q¸³¨Æ (7). ©l¹F¡]¤W®ü¡^ÂåÃĬì§Þ¦³¤½¥q¸³¨Æ (8). Ĭ¦{´º¬RÂåÀø¾¹±ñ¦³¤½¥q¸³¨Æ 8.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¦a§}: (1). ¤W®ü¥«®úªF·s°ÏµØ®L¤¤¸ô393¸¹¤W®ü¬ì§Þ¤j¾Ç¤H¦r¼Ó6¼Ó (2). ¤W®ü¥«¶{¦æ°Ïª÷³£¸ô4299¸¹13¼l2017«Ç1®y (3). ¤W®ü¥«·¨®ú°Ïx¤u¸ô1436¸¹64¼l¤G¼hB®y249«Ç (4). ¤W®ü¥«®}¶×°ÏÀs§d¸ô2046¸¹1¸¹¼Ó1163«Ç (5). ¤W®ü¥«®}¶×°Ïiº¨¸ô25-1¸¹¤G¼h168«Ç (6). ¤W®ü¥«ÀR¦w°Ï¦¿³õ¤T¸ô250¸¹609«Ç (7). ¤W®ü¥«®}¶×°Ï»F¹Å?¸ô789¸¹20¼ÓE1¡BE2«Ç (8). Ĭ¦{¤u·~¶é°Ï¬P´òµó218¸¹¥Íª«¯Ç¦Ì¶éC16¼l |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/18 ¤U¤È 08:52:11
²Ä 3668 ½g¦^À³
|
¤µ¤Ñ·s»D½Z
ASLAN PHARMACEUTICALS APPOINTS DR NEIL GRAHAM AS INDEPENDENT DIRECTOR Singapore, 18 February, 2021 ¡V Dr Graham, an expert in immunology and inflammation, has more than 30 years¡¦ experience in global drug development and commercialisation, traversing early and late-stage clinical trials in dermatology, allergy, rheumatology, virology, and pulmonology. Dr Graham is currently Chief Medical Officer of Tiziana Life Sciences plc (Nasdaq:TLSA, AIM:TILS) and a director of Pharmaxis Ltd. ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Neil Graham, MBBS, MD, MPH as an independent director. Dr Graham was previously the VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., from 2010 to 2020, where he was appointed Global Strategic Program leader for the dupilumab development program from phase 1 through to its commercial launch. Dr Graham also led the product development for KEVZARA (sarilumab), an IL-6R antibody for rheumatoid arthritis, and REGN3500, an anti-IL33 antibody for asthma and COPD. Jun Wu, representative of Alnair Investment, after serving for eight years, has resigned from the board with effect from February 18, 2021, as the fund is reaching the end of its investment cycle. Kelvin Sun, independent director based in Taiwan, will also be stepping down with effect from February 18, 2021, following the company¡¦s delisting from the Taipei Exchange and shift to the Nasdaq Global Market as the company¡¦s sole listing. Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, ¡§We are delighted to welcome Dr Graham to ASLAN¡¦s board of directors. His global expertise in immunology and inflammation, and strategic guidance will be of great value to our team as we approach important milestones in the clinical development of ASLAN004 and ASLAN003 this year. On behalf of the board, I would like to extend our appreciation to Jun Wu and Kelvin Sun for their support and guidance to the management team during ASLAN¡¦s growth.¡¨ ¡Õgoogle ½Ķ¡Ö ASLAN»sÃÄ¥ô©RNEIL GRAHAM³Õ¤h¬°¿W¥ß¸³¨Æ 2021¦~2¤ë18¤é¡A·s¥[©Y¡V §K¬Ì¾Ç©Mª¢¯g¾Ç±M®aGraham³Õ¤h¦b¥þ²yÃĪ«»â°ì¾Ö¦³30¦h¦~ªº¸gÅç ¶}µo©M°Ó·~¤Æ¡A¹M¤Î¥Ö½§¯f¾Ç¡AÅܺA¤ÏÀ³¡A·Àã¯f¾Ç¡A¯f¬r¾Ç©MªÍ¯f¾Çªº¦´Á©M±ß´ÁÁ{§É¸ÕÅç¡C Graham³Õ¤h¥Ø«e¬OTiziana Life Sciences plc¡]Nasdaq¡GTLSA¡AAIM¡GTILS¡^ªºº®uÂå¾Ç©x¡A¤]¬OPharmaxis Ltd.ªº¸³¨Æ¡C ASLAN Pharmaceuticals¡]Nasdaq¡GASLN¡^¡AÁ{§É¶¥¬q§K¬Ì¾Ç ±Mª`©ó¥Íª«»sÃĪº¤½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A ¤µ¤Ñ«Å¥¬¥ô©R¥§º¸¡P®æ¹p¤Ì©i¡]MBC¡AMD¡AMPH¡^¬°¿W¥ß¸³¨Æ¡C Graham³Õ¤h´¿¥ô¬ü°ê¾Ô²¤p¹º«ü¾É¡A§K¬Ì¾Ç©Mª¢¯g°ÆÁ`µô Regeneron Pharmaceuticals¡AInc.±q2010¦~¦Ü2020¦~¡A¥L³Q¥ô©R¬°¥þ²y¾Ô²¤p¹º ±q²Ä1¶¥¬q¨ì°Ó·~µo¥¬ªºdupilumab¶}µop¹ºªº»â¾ÉªÌ¡C³Õ¤h GrahamÁÙ»â¾É¤FÃþ·ÀãIL-6R§ÜÅéKEVZARA¡]sarilumab¡^ªº²£«~¶}µo¡C Ãö¸`ª¢©MREGN3500¡A¤@ºØ°w¹ïý³Ý©MCOPDªº§ÜIL33§ÜÅé¡C Alnair Investment¥Nªí§dx¡]Jun Wu¡^¡A¦b¥ô¾¤K¦~«á¡A¤wÃã¥h¸³¨Æ·|¾°È ¦Û2021¦~2¤ë18¤é°_¥Í®Ä¡A¦]¬°¸Ó°òª÷ªº§ë¸ê¶g´Á§Y±Nµ²§ô¡C®]³Í¤å¡A ¨Ó¦Û¥xÆWªº¿W¥ß¸³¨Æ¤]±N±q2021¦~2¤ë18¤é°_¨ø¥ô¡A ¸Ó¤½¥q±q¥x¥_¥æ©ö©Ò°h¥««á¡AÂಾ¨ì¯Ç´µ¹F§J¥þ²y¥«³õ§@¬° ¤½¥qªº°ß¤@¦Cªí¡C ASLAN Pharmaceuticals¸³¨Æªø¦w¼w¾|¡P»¨¹y¡]Andrew Howden¡^ªí¥Ü¡G¡§§ÚÌ«Ü°ª¿³Åwªï®æ¹p¤Ì©i³Õ¤h¥[¤JASLAN¸³¨Æ·|¡CÀHµÛ§Ú̱µªñ¤µ¦~ASLAN004©MASLAN003Á{§É¶}µoªº«n¨½µ{¸O¡A¥L¦b§K¬Ì¾Ç©Mª¢¯g¾Ç¤è±ªº¥þ²y±M·~ª¾ÃÑ¥H¤Î¾Ô²¤«ü¾É±N¹ï§Ú̪º¹Î¶¤¨ã¦³«n»ùÈ¡C§ÚÂÔ¥Nªí¸³¨Æ·|·PÁÂWu Jun©MSun Kelvin¦bASLAN¦¨ªø´Á¶¡¹ïºÞ²z¹Î¶¤ªº¤ä«ù©M«ü¾É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤U¤È 02:20:45
²Ä 3667 ½g¦^À³
|
×¥¿ ASLAN004欧¬w¤Î¨ä¥L区¾P°âÅv
À³¸Ó·|¦b²Ä¤G´ÁÁ{§Éµ²§ô«e±ÂÅv¡A¨Ó¶Ò¶°²Ä¤T´ÁÁ{§É资ª÷¡C(约¦û25-30%) ¬ü°ê区¤£·|±ÂÅv¡C(¦û¾P°â¤ñ70%¥H¤W)
ªÑ»ù¡H ·|§ó±µªñ60»õ³Ì°ª¾P°â¤Uªº²b²{È¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤U¤È 12:31:16
²Ä 3666 ½g¦^À³
|
²£«~¥un¦³¥¨¤j¼çÈ,¦b¬ü°ê¤£¥Î©È§ä¤£¨ì¸êª÷!!!!!
----------------------
CNBC¡GSpaceX¶Ò±o8.5»õ¬ü¤¸¡B¦ôȸõ¤É¦Ü740»õ¬ü¤¸
1 ¤p®É«e
MoneyDJ·s»D 2021-02-17 10:42:58 °OªÌ ¿à§»©÷ ³ø¾É
© ¥Ñ MoneyDJ²z°]ºô ´£¨Ñ CNBC¶g¤G(2¤ë16¤é)¤Þzª¾±¡¤H¤h³ø¾É¡ASpaceX¤W¶g§¹¦¨·s¤@½ü8.5»õ¬ü¤¸ªÑÅv¿Ä¸ê¡B±a°Ê¦ôȦۥh¦~8¤ëªº460»õ¬ü¤¸¸õ¤É¦Ü740»õ¬ü¤¸¡C³ø¾É«ü¥X¡ASpaceX³Ì·s¤@½üªº¨CªÑ¶Ò¸ê»ù®æ¬°419.99¬ü¤¸¡C
SpaceX¨´¤µ¤w¬°Starlinkµo®g¹O1¤dÁû½Ã¬P¡CSpaceX¤W¶g´£¥æµ¹¬ü°êÁp¨¹³q«H©eû·|(FCC)ªººÊºÞ¤å¥óÅã¥Ü¡AStarlink¦Û3Ó¤ë«e¤½¶}´ú¸Õ¥H¨Ó¡B¬ü°êµ¥¦a¥Î¤á¼Æ²Öp¤w¶W¹L1¸U¡C
°¨´µ§J¡GSpaceX¶·¸ó¹Lt²{ª÷¬yªº²`¼hÂE·¾
SpaceX°õ¦æªø°¨´µ§J(Elon Musk)¤é«e±À¤åªí¥Ü¡ASpaceX¥²¶·¦b¥¼¨Ó¤@¦~¥ª¥k¸ó¹Lt²{ª÷¬yªº²`¼hÂE·¾¡B¥H«KÅýStarlinkªº°]°Èª¬ªp¤îáC
°¨´µ§JÁÙ»¡¡A¾ú¥v¸gÅçÅã¥Ü¡B¨C¤@®a·sªº½Ã¬PªA°È¤½¥q³Ì²×³£¥H¯}²£¦¬³õ¡A§Æ±æ¦Û®a¤½¥q¯à¦¨¬°²Ä¤@®a¥´¯}±J©Rªº·~ªÌ¡C
°¨´µ§J¥h¦~©³±À¤åªí¥Ü¡A¤@¥¹À禬¦¨ªø¥i¥H¦X²z±À¦ô¡AStarlink´N«Ü¦³¥i¯à·|¤½¶}¤W¥«¡C
Starlink¡G¬ßFCC½á¤©¡u¦X®æ¹q«H·~ªÌ¡v¸ê®æ
SpaceXµo¥¬ªº¤å¥ó¤W´£¨ì¡AStarlink Services, LLC¥§¡¨CÓ¤ë¶i¦æ¨â¦¸ªº½Ã¬Pµo®g¡A¤w³z¹LStarlinkºô¸ô¦¨¥\¦a´ú¸Õ¿W¥ß»yµªA°È¡C
Starlink´Á¬ßFCC¯à°÷¦b2021¦~6¤ë7¤é¥H«e§åã½ÐÄ@®Ñ¡B½á¤©¡u¦X®æ¹q«H·~ªÌ(ETC)¡v¸ê®æ¡A¥H«KÅý¥¦¥i¥H¶¶§Q¨ú±o¡u¬ü°ê¹A§ø¼Æ¦ì¾÷·|°òª÷(RDOF)¡vªº¤ä´©¡C
Starlink Services±N´£¨Ñ¥þ²yº¨£°ª¶Ç¿é³t«×¡B§C©µ¿ðªº½Ã¬Pºô»Úºô¸ôªA°È¡A²Î¦X¥@¬É¤W³Ì¤j³W¼Òªº¹B¦æ½Ã¬P¸s¡B¬°¥þ²y³ÌÃø¥H³sºô¦a°Ï(¥]¬A¬ü°ê¦b¤º)´£¨Ñ¤@PªºªA°È¡C
ªÅ¤¤¤Ú¤h(Airbus)¤ÓªÅ¨t²Î¥h¦~©³«Å¥¬¡A¼Ú·ù°õ©e·|¤w¬D¿ï¥X¥Ñ¼Ú¬w½Ã¬P»s³y°Ó/Àç¹B°Ó/ªA°È¨ÑÀ³°Ó¡B¹q«H°Ó¥H¤Îµo®gªA°È°Ó²Õ¦¨ªºÁp·ù¡A¥Ø¼Ð¬O¬ã¨s¼Ú¬w¤ÓªÅ³q«H¨t²Îªº³]p¡B¶}µo©Mµo®g¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 10:46:22
²Ä 3665 ½g¦^À³
|
ªi§J®L´î½XÄ«ªG¡Bª÷ÄqªÑ¥þ½æ¡I·s¼W³·¦òÀs¡BVerizon
1 ¤p®É«e
úç
¾G¤HºÓ²¢»e¤½¶}©ñ°{¡I¾D»Ä¥Á«ã¶æ¡uª¯¨k¤k¡v ¤pÂȺI¹Ï¦^À³ úè
°ê1¤Æ¾Ç¼Ñ¨®Â½ÂСIA9ªL¤f¯¸¼È°±Àç¹B °õ¦æ¤½¨®±µ»é
MoneyDJ·s»D 2021-02-17 08:59:52 °OªÌ ³¢§°§Æ ³ø¾É
© ¥Ñ MoneyDJ²z°]ºô ´£¨Ñ ¬ü°ê§ë¸ê¤j®vµØÛ¤Úµá¯S(Warren Buffett¡B¨£¹Ï)´xºÞªºªi§J®L®ü·æ«Â(Berkshire Hathaway)¡A¶g¤G(2¤ë16¤é)«Å¥¬¨â¤j¥þ·s§ë¸ê¶µ¥Ø¡A¤À§O¹ï¬ü°ê¹q«H¥¨À¼Verizon Communications Inc.¡B¬ü°ê¥Ûªo¥¨À¼³·¦òÀs(Chevron Corp.)§ë¸ê¤F86»õ¬ü¤¸¡B41»õ¬ü¤¸¡A¥t¥~¨Ã³{°ª¥X²æÄ«ªG(Apple Inc.)¤@³¡¤À«ùªÑ¡AÁÙ§âª÷ÄqªÑ¥þ³¡½æ¥X¡C
¸ô³zªÀ¡BYahoo Finance¡BZero Hedge³ø¾É¡Aªi§J®L16¤é§e¥æªº13F©u«×³ø§iÅã¥Ü¡AºI¦Ü2020¦~12¤ë31¤é¬°¤îªº²Ä¥|©u´Á¶¡¡AºX¤U·s¼W¤F4,850¸UªÑ³·¦òÀsªÑ²¼¡B»ùÈ41»õ¬ü¤¸¡AVerizon«h´¤¦³1.476»õªÑ¡B»ùȬù86»õ¬ü¤¸¡A¦¨¬°§ë¸ê²Õ¦X¤¤³W¼Ò²Ä¤»¤j³¡¦ì¡C
ªi§J®L¤]±N¹qµø¥x¡B³ø¯È¡B¼Æ¦ì´CÅéºô¯¸¸gÀç°ÓThe E.W. Scripps Company¥[¤J§ë¸ê²Õ¦X¡A«ùªÑ¼Æ¹F2,307¸UªÑ¡C¿Ô¸ß¡B·ÀIµû¦ô¡Bµ¦²¤¡B¤H¤O¸ê¥»µ¥¸Ñ¨M¤è®×´£¨Ñ°ÓMarsh & McLennan Cos¤]¬O·s¼W«ùªÑ¡A«ùªÑÁ`ÃB4.99»õ¬ü¤¸¡C
¤½§i¨ÃÅã¥Ü¡Aªi§J®L¥[½X¶R¶iªº»sÃÄÃþªÑ¥]¬A¬ü°ê¥Íª«»sÃĤ½¥qAbbVie Inc.¡B¬ü°êÃļt¥²ªv§´¬I¶QÄ_(Bristol-Myers Squibb Co.)¤Î¬ü°ê»sÃÄ¥¨À¼Àq§JÃļt(Merck)¡A³o¨Ç³¡¦ì³Ìªì¬O¦b2020¦~Q3´¦ÅS¡Cªi§J®L¤w±N½÷·ç(Pfizer)«ùªÑ¥þ¼Æ¥X²æ¡C
¥t¤@¤è±¡Aªi§J®L±NÄ«ªG«ùªÑ«d´î¬ù6%¡A¥X°â¤F5,716¸UªÑ¡C¤£¹L¡AÄ«ªG¤´¬Oªi§J®L³¡¦ì³Ì¤jªºªÑ²¼¡A«ùªÑÁ`ÃB¬°1,210»õ¬ü¤¸¡C
ªi§J®L¦P®É±N¼¯®Ú¤j³q(JP Morgan Chase)¡BPNCª÷¿ÄªA°È¶°¹Î (PNC Financial Services)ªº³¡¦ì¥þ³¡°â¥X¡A´I°ê»È¦æ(Wells Fargo)«ùªÑ«d´î¬ù58%¡B¥X°â7,495¸UªÑ¡A¬ü°ê¦X²³»È¦æ(U.S. Bancorp)¤]¾D¨ì´î½X¡Cªi§J®L¥Ø«e¬O¬ü°ê»È¦æ(Bank of America Corp.)ªº¤jªÑªF¡C
ªi§J®L¤w±Nª÷Äq°Ó¥[®³¤j¤Ú·ç§J¶Àª÷¤½¥q(Barrick Gold Corporation)ªºªÑ²¼¥þ³¡½æ¥X¡C³oÓ³¡¦ì¬O¦b2020¦~Q2º«×´¦ÅS¡C
ªi§J®L¤]±N³q¥Î¨T¨®(General Motors)«ùªÑ«d´î750¸UªÑ¡AQ4©³ªº³¡¦ìÁ`ȨӨì30»õ¬ü¤¸¡C
Seabreeze Capital Investment Inc.¸g²z¦X¹Ù¤HDoug Kass«ü¥X¡Aªi§J®L§ë¸êVerizon¬O¬Û·í¦X²zªº¨Mµ¦¡A¤Ï¬M¸Ó¤½¥qªºªÑ®§°tµo¡BµL½uºô¸ôÀ禬¦¨ªø«e´º¡Cªi§J®L´î½X»È¦æªÑ¡A¥i¯à¬O¦]¬°¤Úµá¯S¹ï«ùÄò§C°gªº§Q²v¡B¬Ì±¡¤Þµoªº§b±b°ÝÃD·P¨ì¼~¤ß¡C
ªi§J®L§Y±N¦b2¤ë27¤é¤½¥¬2020¦~©³ªº°]³ø¥H¤Î¤Úµá¯Sªº¦~«×ªÑªF«H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 07:03:11
²Ä 3664 ½g¦^À³
|
×¥¿ ¦©°£0.3¡Ñ18/5=1.08»õ¬ü¤¸ªºùµ{ª÷¡A 约2.9»õ²{ª÷¥i¥Î©ó004 AD¤T´ÁÁ{§É¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 06:20:41
²Ä 3663 ½g¦^À³
|
ASLAN004 欧¬w¤Î¨ä¥L区¡AÀ禬预¦ô60»õ¬ü¤¸x30%=18»õ¬ü¤¸¡C ¥iÄw资ª÷约1,1¡Ñ18/5=3,96»õ¬ü¤¸ªºÃ±¬ùª÷+约50%¾P°â¤À¼í ¦©°£0.3¡Ñ1.1»õ¬ü¤¸ªºùµ{ª÷¡A约3.5»õ²{ª÷¥i¥Î©ó004 AD¤T´ÁÁ{§É¡C
¥H¤U¬O¨Ì¾Ú欧¬w¥i¾P°â5»õ¬ü¤¸AD¡Aªº±ø¥ó©Òq¡C ¤T´Á¥ÑDermira°µ§¹¡A¨ú±oÃĵý«á¥ÑAlmirall¾P°â¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í?(¤À¼í¤ñ²v¥i¯à1¡G1) ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 02:52:51
²Ä 3662 ½g¦^À³
|
REGN¤½¥qªº²Ä¤@Ó¤jÃÄEylea¤W¥«®É¡A¬ü°ê区¥H¥~¬O±ÂÅv给«ô¦Õ¤½¥q¾P°â¡C
Dupilumab 欧¬w区¬O¥Ñªk°ê赛诺µá销°â¡C
¤p¤½¥qµLªk¤@®É«Øºc¥þ²y销°âºô¡C
¬G¶È«O¯d¬ü°ê¦Û销¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 02:41:47
²Ä 3661 ½g¦^À³
|
欧¬w¤Î¨ä¥L区À³¸Ó·|¦b²Ä¤G´ÁÁ{§É«e±ÂÅv¡A¨Ó¶Ò¶°²Ä¤T´ÁÁ{§É资ª÷¡C(约¦û25-30%) ¬ü°ê区¤£·|±ÂÅv¡C(¦û¾P°â¤ñ70%¥H¤W)
ªÑ»ù¡H¤£ª¾¹D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/17 ¤W¤È 02:30:58
²Ä 3660 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/2/3 ¤W¤È 11:24:04²Ä 3603 ½g¦^À³ ¨È狮³Ì°ª»ùȦb¦Û°µ¤T´Á¡A¦Û¦æ¾P°â
¯à¨«¦h»·¡H随顺¦]½t¡I
¨È·à ¥¼¨Ó¥«È/ADRªÑ»ù¤§¹w¦ô
1.2021¦~7¤ë°µ§¹ASLAN004 1b ADÁ{§É, ¨È·à³QÁʲ{ª÷»ùÈ: 30»õ¬ü¤¸ ADR 54¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ> ---Y¥[ASLAN003(2b MSÁ{§É¶}©l) 5»õ¬ü¤¸, ¨È·à³QÁʲ{ª÷»ùÈ: 35»õ¬ü¤¸----- ADR 63¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
2.2022¦~12¤ë°µ§¹ASLAN004 2b ADÁ{§É, µ²ªG¦p¹w´Á ¨È·à³QÁʲ{ª÷»ùÈ: 35»õ¬ü¤¸ ADR 63¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
---Y¥[ASLAN003(2b MSÁ{§É§¹¦¨) 7»õ¬ü¤¸, ¨È·à³QÁʲ{ª÷»ùÈ: 42»õ¬ü¤¸----- ADR 75¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
3.2024¦~12¤ë°µ§¹ASLAN004 3´Á ADÁ{§É µ²ªG¦p¹w´Á, ¨È·àADR ¥«È60»õ¬ü¤¸´Á±æÈ ADR 90¬ü¤¸/ªÑ---¸ê¥»ÃB67,000¤dªÑ>
---Y¥[ASLAN003(2b MSÁ{§É§¹¦¨) 7»õ¬ü¤¸, ¨È·àADR ¥«È: 67»õ¬ü¤¸----- ADR 100¬ü¤¸/ªÑ---¸ê¥»ÃB67,000¤dªÑ>
4.2026¦~3¤ë¤W¥« 3Ó¤ë,¦Û¤v¾P°â , ¨È·àADR ¥«È150»õ¬ü¤¸´Á±æÈ/¥¼¨Ó¾P°â¨ì60»õ¬ü¤¸
ADR 180¬ü¤¸/ªÑ---¸ê¥»ÃB80,000¤dªÑ> ---¥¼¦ôASLAN003»ùÈ
5.2026¦~12¤ë ~2027¦~,¤W¥«¾P°â¶W¶V¹w´Á,´£°ª¥¼¨Ó¾P°â¨ì100»õ¬ü¤¸
¨È·àADR ¥«È250»õ¬ü¤¸´Á±æÈ ADR 300¬ü¤¸/ªÑ-¸ê¥»ÃB80,000¤dªÑ> ---¥¼¦ôASLAN003»ùÈ
----------------------- (ASLAN003 2b MS Á{§É§¹¦¨, ¬ù10»õ¬ü¤¸¾P°â/7»õ¬ü¤¸§é²{¼çÈ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gellelin10138869 |
µoªí®É¶¡:2021/2/17 ¤W¤È 01:51:12
²Ä 3659 ½g¦^À³
|
¤Ñ©R¤j¤j¡A·Q½Ð±Ð¡A ¤£ª¾¹D¬O§_¥i¯à¦b¤µ¦~1b´Á¤¤¸Ñª¼¼Æ¾Ú¤Î¦~¤¤³ø§i¤½§G«á¡A ´£¦±ÂÅv©O¡H °O±o¤Ñ©R¤j´¿´£¹L³o¥i¯à©Ê¡A½Ð±Ð³o³¡¥÷¥i¯à©ÊÁÙ¦s¦b¶Ü¡H ¬O§_ÀHµÛn¼W¸êp¹º¤j¤j°§C©O¡H
¦pY±ÂÅv´£¦¦b¤µ¦~µo¥Í¡A¨ºªÑ»ù⋯¯à§_¹w´ú±ÂÅv«áªÑ»ù©O¡H ·PÁ¤ѩR¤j¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/2/17 ¤W¤È 01:07:23
²Ä 3658 ½g¦^À³
|
·à¤l¥h¦Ì°ê¬O¹ïªº¡A ¬Û«H¥xÆWÁÙ¦³«Ü¦h·sÃĬO«Ü¦³¾÷·|ªº...
003/004 ³£¬O«Ü¦³¼ç¤OªºÃĪ«¡A²{¦bªÑ»ùÁÙºâ¬O²¢²¢»ù... ¸êª÷¤w¸g¥Î±o®t¤£¦h¤F¡A§Ú´N«Ê½L¡AÀH¹J¦Ó¦w |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/2/16 ¤U¤È 11:26:16
²Ä 3657 ½g¦^À³
|
¤@®a¤p¤½¥q¦¨¥\¬ãµo¤@Áû¤jÃÄ»P¤@®a¤j¥Í§Þ¤½¥q¦¨¥\¬ãµo¤@Áû¤jÃĨäÃzµo¤O·|®t«Ü¤j¡A§Y¨Ï¬O¦´Á¬ãµo¶¥¬q¨äÃzµo¤O¤£¥i»´©¿¡A ¤£»Ý¹w³]»ù¦ì¡C ·à¤l¥Ø«e»ù¶q¬O¦b¤Þ°_§ë¸ê¾÷ºcª`·Nªº¶¥¬qcall attention ¡A°£«D·¥»Ý¥Î¿ú¡A¼Æ¾Ú¤½§i´N»´©ö½æ¥X¬O§_¥¿½T¡A¥u¯à¥Î®É¶¡¨ÓÃÒ©ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/16 ¤U¤È 11:07:32
²Ä 3656 ½g¦^À³
|
¤µ¤Ñ¶q«Ü¤j è¤@«×º¦¨ì4.26¡A¤£¹L¤S³QÀò§Q¤Fµ²ªº¤H½æ¤U¨Ó §Ú»{¬°ÁÙ¬O½wº¦¨ì¼Æ¾Ú¥XÄl¤~¬O³Ì°·±dªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/16 ¤U¤È 10:33:49
²Ä 3655 ½g¦^À³
|
´Á¤¤¼Æ¾Ú¤@¤½¥¬¡A¤j®a¥i§PÂ_M0AÅçÃÒ¦¨¥\¡C
004ªºÀø®Ä¡AESAI¥§¡°´T¦ô约¹ï·Ó组ªº300%
°ê»Úªº¨ÖÁʬ¡°Ê·|¿n·¥¶}©l¡C
¦X¤@ªºFB825¡A´¿¦³¥@¬É«e¤¤jÃĤ¤ªº¤G¤j°Ñ»P±ÂÅv¡A¨Ã¥X»ù¡C
¹ï©óÓ·m¹ÜDupilumab ¤@¥b¥«Ô·ªº·sÃijq¹LMOAÁ{§É¸gÅç¡C ¬O¦óµ¥¤j¨Æ¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/2/16 ¤U¤È 10:23:17
²Ä 3654 ½g¦^À³
|
something happened ! ASLN¡@èè½L«e±¾¤F 199K »ù¦ì3.89 ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/15 ¤W¤È 08:39:05
²Ä 3653 ½g¦^À³
|
003 MS 2aÁ{§É©|¥¼¶}©l¡C
004 1b ©µ¦ù©ÊÁ{§É(12+6¤H)¡A¦~¤¤¤½¥¬¼Æ¾Ú¡C(¤½¥q·s»D½Z/¤¸¤ë11¤é) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/15 ¤W¤È 08:14:42
²Ä 3652 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j 003/004ªº1B³Ì²×Á{§É¼Æ¾Ú ¤½¥¬ªº®É¶¡¤j¬ù·|¦b¦ó®É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/14 ¤U¤È 10:37:16
²Ä 3651 ½g¦^À³
|
¶Ò¸ê1.5»õ¬ü¤¸¦¨¥\ªº±ø¥ó
¦]¬°®Ú¾Ú¬ü°êªk«ß¥i¶ÒªÑ¼Æ¶È¬ù7100¤dªÑADR.¡X¡X-¥Ø¼Ð³Ì§C¥§¡»ù¦b21¬ü¤¸/ADR.
21x(36000¡Ï3326¡Ï7100)¤zªÑ=8.4»õ¬ü¤¸¡]ªÑ»ù¥«È¡^¡X¡X²Å¦X¤@¯ëMOAÁ{§É³q¹Lªº·sÃÄ¥«È¬ù8-10»õ¬ü¤¸¡C
¦ý¶È¬°004 ¥i±ÂÅv²bȬù30»õ¬ü¤¸ªº8.4/30=28%.
ªÑ»ù·|¦p¦ó¶]¯uªº¤£ª¾¹D!
2019¦~12¤ëªì 0.36 ¤jº¦¦Ü8.18¬ü¤¸¡A¶È¤½¥¬3¦ì¼Æ¾Ú.
¥»¦¸¤½¥¬24¦ì¡A°ª©ó8.18¬O¥²µM¡A·|©Ô°ª¦h¤Ö¤£ª¾¡A
ÁôÂåؼлù21¬ü¤¸
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/14 ¤U¤È 09:12:42
²Ä 3650 ½g¦^À³
|
·PÁ©ú¤Ñ¹L«á¤jªº¸gÅç¤À¨É¡I½Ð°Ý¤Ñ©R¤j«ç¤\¬Ý¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/2/14 ¤U¤È 08:46:31
²Ä 3649 ½g¦^À³
|
¥»¤H¹ï¬üªÑ¥Í§Þ¦³¤@ÂI¬ã¨s»¡¥X¥H¤U¬ÝªkÅý¤j®a°Ñ¦Ò¤@¤U,®Ú¾Ú¤§«e§ë¸ê¹L¬üªÑ´X°¦¥Í§ÞªÑ,¦ýì«h¬O¼Æ¾Ú³£¨}¦nª¬ªp¤U»ù®æ¥¼¨ÓªºÅܤƨӮM¥ÎASLN»ù®æ±a¹w´ú ! ¥H¤U¤£¾A¦Xnµ¥¨ì2Bµ²ªG¥XÄlªº§ë¸êªÌ !!
*****»ù®æ³Ì¤jÅܤƲĤ@®É¶¡ÂI : ASLAN expects to report interim, unblinded data from all three dose escalation cohorts in early 2021. ¥H¤W(unblinded data)«Dª¼¼Æ¾Ú>>>³oÓ¬O¦b»¡¦b°Ñ»PªÌ¤F¸Ñ«n¨Æ¹êªº±¡ªp¤U°µ¥X©Î§¹¦¨ªº¤£¬Oª¼¥Øªº¹êÅç,°²³]¼Æ¾Ú¼ÖÆ[»ù®æ¥i¯à·|Ãk¤É50%~100% #####®É¾÷ÂI¸¨¦b2021Q1¥ª¥k,°²³]·í®É»ù®æºû«ù¦bUSD$3¦³¥i¯à¤@¤Ñ´N¸õ¤É¨ìUSD$6(¦ý¤§«áªÑ»ù·|©¹¤U¾_Àú)
*****»ù®æ³Ì¤jÅܤƲĤG®É¶¡ÂI : followed by data from the expansion cohort in mid-2021 ³oÓ´N«n¤F,¥H¤W´N¬On¦b2021¦~¤¤´Á´£¨ÑÂX®i²Õªº¼Æ¾Ú,¦pªG¼Æ¾Ú¨}¦n°²³]¼Æ¾Ú¼ÖÆ[»ù®æ¥i¯à·|Ãk¤É100%~150% #####®É¾÷ÂI2021¥ª¥k°²³]·í®É»ù®æºû«ù¦bUSD$4¦³¥i¯à¤@¤Ñ´N¸õ¤É¨ìUSD$6(¦ý¤§«áªÑ»ù·|©¹¤U¾_Àú)
*****»ù®æ³Ì¤jÅܤƲĤT®É¶¡ÂI : ´N¬O¼W¸êUSD$150,000,000ªº³¡¤À,¯¸¦b¤½¥q¥ß³õ¤@©w¬O§Æ±æ¸êª÷¤@¦¸¨ì¦ì¤£n¤À¦h¦¸¼W¸ê,©Ò¥H¼W¸ê®É¾÷ÂI«Ü¦³¥i¯à¦b2021¦~¤¤´Á´£¨ÑÂX®i²Õªº¼Æ¾Ú¤§«á,¦pªGµo¥¬¼Æ¾Ú¤£¿ù,¤½¥q¬£·|Âǥѥ«³õ¥D¤O&´²¤áºCºC±À¤É»ù®æ!¨ì¤F¤@©wªº®É¾÷ÂI´N·|¤½¶}µo¦æ»ù®æ§¹¦¨©w»ù ! #####®É¾÷ÂI2021Q2°²³]·í®É»ù®æºû«ù¦bUSD$5,µM«á¥«³õ¥D¤O&´²¤áºCºC±À¤É¨ìUSD$6~7,¤½¥q«Å¥¬³Ì«á»ù®æ¦³¥i¯à¤@¤Ñ´N¸õ¤É¨ìUSD$12¥ª¥k!
©Ò¥H¦U¦ì§ë¸êªÌ¥i¥H°Ñ¦Ò§Ú¥H¤WªÑ»ùÅܤƪº®É¾÷ÂI!´¿¸g¦³¤@°¦¥Í§Þ¬üªÑ»ù®æ0.87¤@¸ô«ö§Ú¤W±±Ôz,²Ä¤T®É¾÷ÂIöt¨ì11.25, µM«á¤@¸ô¦^¶^³Ì§C¨ì3.85,¤§«á²{¦b¤SºCºCª¦¤É¨ì6.9¥ª¥k!©Ò¥H¤£ª¾¹D¦p¦ón½æ¥Xªº§ë¸êªÌ¥i¥H°Ñ¦Ò ! §ÚÓ¤H»{¬°¥H2021¨Ó»¡³Ì¨Î½æ¥Xªº®É¾÷ÂI±N¸¨¦b¤½¶}µo¦æ»ù®æ§¹¦¨©w»ù®É!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/13 ¤W¤È 09:40:28
²Ä 3648 ½g¦^À³
|
·à¤l¤w¸g³sº¦10¤Ñ Åý¤j®a¦~°²¤ß±¡«Ü¦n ¬Æ¦Ü¦³ÂI²ßºD·à¤l¤Ñ¤Ñº¦ªº¤é¤l
¥Ø«e¶q»ù³£ºû«ù±o¤£¿ù §¹¥þ²Å¦X§Ú»¡ªº³Ì¦n¬O½wº¦¨ì¼Æ¾Ú¥X¨Ó ¯¬ºÖ¤j®a¤ûÂà¿ú©[¡A¤û¦~§ë¸ê¤j¶¶§Q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/2/13 ¤W¤È 12:45:41
²Ä 3647 ½g¦^À³
|
è観¤@µ§100¸UªÑªº¹ï»ù¦¨¥æ¥x¹ô±Nªñ¤@»õ ! ÁÙ®¼Åå¤Hªº À³¸Ó¬O©e°U²Ä¤T¤è¥X°âªº¶R½æ ! ¨ì©³¬Oþ¤@Ó¤j©@¶R¤J .. ¯u¬O¦n©_ ! ³q±`½L¤¤¤jµ§¶R½æ¦³¥i¯à¬Oµo°Êº¦¶Õªº¶}©l ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/11 ¤W¤È 08:36:03
²Ä 3646 ½g¦^À³
|
ªÑ¥«±`±`·|¶^·|¶^¯}²³¤H²´Ãè¡Aº¦¬Oº¦¨ì¶W©I ·Q¹³ ¦X¤@±ÂÅv5»õ¬ü¤¸¡Aº¦¨ì500¤¸¤Ñ»ù¡Aµ¥003/004 ªºÁ{§É®ÄªG¥X¨Ó¡A¥i¥Hº¦¨ì¦X¤@¤@¥b»ù®æ¤]´N º¡¨¬¤F ¤µ¦~¤û¦~¡A´NÅý³oÀYª÷¤û±a»â¦U¦ìªÑªF¤j¤j ½Ä¥X¤@Ó¤£¤@¼Ëªº®æ§½ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gellelin10138869 |
µoªí®É¶¡:2021/2/10 ¤U¤È 08:38:27
²Ä 3645 ½g¦^À³
|
·PÁ¤ѩR¤j¤£¹½¨ä·Ðªº¬°·à¤ÍÌ»`¶°¤À¨É¤Î¤ÀªR¸ê°T¡I §Ú¤]¬O±q4*¶R¤U¨Óªº¡A¦nÀI¤@¸ô¤W¦³¤Ñ©R¤j¡B¥xÁÞ¤j¤Î¦U¦ì·à¤Í̪º¤À¨É¡A ¥»¨Ó°±·l±þ¥X¡A«á¨Ó¤S¦b¥xªÑ£¸¤ù¤£¬Ý¦n¨ì·Ç³Æ¤U¥«´Á¶¡³°Äò¶R¦^¡I Âà´«ADR´Á¶¡¤]¦nÀI¦³¦U¦ì¤À¨É¸gÅç¡A¦p¤µ¶¶§Q§¹¦¨¡B¥u«Ý¶}ªáµ²ªG¤F¡I ¤W¦¸¦³Ó·à¤Í¦³°Ý¬O§_¥[½X¡A§ÚÓ¤H¦³³á¡I ¦ý§Ú¬O¥Îfirstrade±b¤á¥[½X¡A¥Î½Æ©e°U¤âÄò¶O¤Ó¶Q¤FXD ¥Ø«e¨C¤Ñ³Ì´Á«Ýªº´N¬O¨C¤Ñ¨êª©¬Ý¦U¦ì¯d¨¥¡AÀR«Ý®ø®§Åo¡ã ·à¤ÍÌ·s¦~§Ö¼Ö¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2021/2/10 ¤U¤È 07:42:31
²Ä 3644 ½g¦^À³
|
·PÁ¤ѩR¤j¡A
¨C¤Ñº¦ªº·Pı¯u¦n¡A¥[ªo¡A¨È·à¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/10 ¤U¤È 06:46:29
²Ä 3643 ½g¦^À³
|
¨È狮¥«È1.38»õ¬ü¤¸
谮¦b³Q¨ÖÁʲ{ª÷»ùÈ
004 30»õ¬ü¤¸ 003 5»õ¬ü¤¸ ¦Xp 35»õ¬ü¤¸
¨ÖÁʪ̥t须¤ä¥ICSLµ¥¤W´å¦X约À³¥Iùµ{ª÷¤Q¤À¼í
²{¶¥¬q´NÅý¥«³õ°l谮È¡C
Ãø±o¤@¹J¤§¼Ðªº¡C®¥³ß¤x¦b¤õ½b¤WªºªÑªF¡A¤½¥¬¸Ñª¼¼Æ¤@¤Ñ¤jº¦N%¤é¤l¡AÀ³¸Ó¦b¹A¾ä¦~«á¡C
¤j®a¤û¦~§Ö¼Ö¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/9 ¤U¤È 01:20:11
²Ä 3642 ½g¦^À³
|
¦ó´¹¤µ¦~10¤ë°h¥ð¡A²H°¨锡CEO´«¤H°µ¡C m.cnyes.com/news/id/4567096 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/8 ¤U¤È 03:41:12
²Ä 3641 ½g¦^À³
|
¦X¤@ FB825 °µ§¹IV 12¦ìAD ************ 5.3»õ¬ü¤¸Ã±¬ùª÷+¾P°â¤À¼í±ÂÅvµ¹LEO ************* ªÑ»ù¨¤@ªi¤jº¦200¤¸(30¤¸~233¤¸)
200*35.5=710»õ¥x¹ô/¬ù25»õ¬ü¤¸.
-------------------------------------------------- ¥¼¨ÓASLAN004 Y¥þ²y±ÂÅv±ø¥ó
¥i¯à¦p¤U: ************ 30»õ¬ü¤¸Ã±¬ùª÷+¾P°â¤À¼í±ÂÅv ************* ¤Wz§tCSL 7.3»õ¬ü¤¸Ã±¬ùª÷+¾P°â¤À¼í±ÂÅv
¨È·à±d¤½¥q¬ù ,22.7»õ¬ü¤¸Ã±¬ùª÷+¾P°â¤À¼í±ÂÅv
22.7/5.3=4.28 ¿©ó¦X¤@ªºFB825ñ¬ùª÷
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/8 ¤U¤È 03:21:33
²Ä 3640 ½g¦^À³
|
§Æ±æ¨È·àªº¥D¤O&¤½¥q ³¥¤ß¤j¤@ÂI,¤@¦¸¦pAnaptysBio ¤jº¦¨ì30 »õ¬ü¤¸¥«È,
30*80%*7100/(36,000+3326)=4.3»õ¬ü¤¸¥i¶Ò±o.----¥Ø¼Ð¥§¡ADR°â»ù60¬ü¤¸.
--------------------------------------------
¨È·àªºASLAN004 1bÂùª¼´n©À©ÊÁ{§É¹LÃö. ¥NªíMOA¸gÅçÃÒ¹LÃö,p< 0.05 »P¹ï·Ó²Õ¦³²Îp¤WÅãµÛ®t²§
¥»¦¸ASLAN003 AD ´Á¤¤³ø§i ¦ôp ESAI ¥§¡°´T/8¶g
(1)ASLAN004 77% +/-3% (®Ú¾Ú2019/12/03 ¨È·à¤w¤½§G¤T¦ì¥¼¸Ñª¼,>4¶g, ¥§¡ESAI °´T71%¦ô) (2)¹ï·Ó²Õ 25% +/-2% (®Ú¾Údupilumab ¤T´ÁÁ{§É¹ï·Ó²Õªº²Ä8¶g¸ê®Æ,¥§¡ESAI °´T20%~23%¦ô(3) ) (1)/(2)=300%
***dupilumab ¤T´ÁÁ{§Éªº²Ä8¶g¸ê®Æ ¬ù63%~67%(4)---¨C¶g¤@°w. (4)65%/(3)21.5%=300%
www.nejm.org/doi/full/10.1056/nejmoa1610020 ¹Ï¤G
¦pdupilumab ªºÀø®Ä, µLdupilumabµ²½¤ª¢¤§°Æ§@¥Î ¥¼¨Ó¥i¥´¤@°wvs. dupilumab ¤G¶g¤@°w (¥i¤j´T°¦~Àøµ{¶O¬ùdupilumab 64% )
----------------------------------------- ¬ü°ê 1b ¤¤««× AD Á{§É ªÑ²¼, §ë¸ê´A¤O!
---------------------------------------------------- ASLAN004 24¦W,¤¤««× AD ·§©À©ÊÁ{§É¼Æ¾Úªº±N¤½¥¬ ¦P¯e¯f³Ì¨ÎASLAN004, ¬O§_¦³ AnaptysBio ,4-5Ó¤ë¡A ¤jº¦ 24»õ¬ü¤¸ªº¾÷·|? ¤@¦¸¤ÏÀ³ ?
----------------------------- AnaptysBio ,IL33 ªvÀø¤¤««×AD ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vµo¥¬12¦W·§©À©ÊÁ{§É¥¿¦V¼Æ¾Ú¡C
ªÑ»ù2017¦~10¤ë«Å¥¬«e32¬ü¤¸¡A³sº¦4-5Ó¤ë¡Aº¦¥|¿¡A³Ì°ª128¬ü¤¸¡A±q¥«È8»õ¬ü¤¸¡Aº¦¨ì32»õ¬ü¤¸¡C ------------------------------------
¥i±¤«e2Ó¤ë¡A2019¦~11¤ë8¤é¤½¥¬2b/300¤HADÁ{§É¸Ñª¼¥¼¹LÃö¡C ªÑ»ù¦^15¬ü¤¸¡A³Ñ¥|»õ¬ü¤¸¡C www.marketwatch.com/investing/stock/anab |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/8 ¤U¤È 12:17:12
²Ä 3639 ½g¦^À³
|
¥»¦¸´Á¤¤³ø§i¤½¥¬«e¯à¤jº¦§_¹L2019¦~12¤ëªì°ªÂI8.14¡H ¤½¥¬«á´Á¤¤¸Ñª¼¼Æ¾Ú«á¦A¤jº¦¤@¿16¬ü¤¸¡A ¦Aº¦¨ì¦~¤¤´Á¥½³ø§i¤½¥¬¡A¯¸¤W25¬ü¤¸¡A ´Á¶¡¥§¡°â»ù21¬ü¤¸¡þªÑx7100¤dªÑADR=1.5»õ¬ü¤¸¡A¹F¥«È20x(36000¡Ï3236¡Ï7100)=10»õ¬ü¤¸¥ª¥k¡C
³o¬O²q´ú¶Ò¸ê¦¨¥\ªº¥i¯à¸ô®|¤§¤@¡C
¦A©ú¦~©³¦~°µ§¹2b«á¡A¦A¶Ò3~5»õ¬ü¤¸¡A°µ¤T´Á 400x2¤HADÁ{§É
¥i¶Ò(3236¡Ï7100)X1.3=13,500¤dªÑADR
5»õ¬ü¤¸/13,500¤dªÑ=ªñ40¬ü¤¸¥ª¥k/ªÑ , ADR¡]2022¦~12¤ë¡^
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/7 ¤U¤È 01:16:38
²Ä 3638 ½g¦^À³
|
2021¦~Dupilumab ¦ôp¾P°â 57~58»õ¬ü¤¸
¡X¡X¡X¡X¡X¡X¡X¡X 2020¦~²Ä¥|©u°]³ø¤½¥¬¡ADupilumab ¥þ¦~¾P°â¹F40.4»õ¬ü¤¸.
investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2020-financial
Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA ROW ¤pp 2020 Q1 679.0 174.2 853.2 Q2 770.4 176.6 947.0 Q3 851.2 221.4 1072.6 Q4 925.6 246.4 1172.0 ¤pp3226.2 818.6 4044.8
2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6
2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0
2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/7 ¤W¤È 08:40:09
²Ä 3637 ½g¦^À³
|
ASLAN004¤§M0AÅçÃÒ
¤@.1a °·±d¤H42¤Hªº¦w¥þ©ÊÁ{§É¡A2019/05/31§¹¦¨
Æ[¹î¦å²G¤¤ªºSTAT6¡A´N¬OII«¬¨üÅé²Õ¦¨«áªº¤ÏÀ³ª«½è¡C ¦bASLAN004IVª`®g¤@¤p®É«á¡A§Y³QªýÂ_¡A¥NªíM0A¦¨¥\¡C
¤G¡B1b ·§©À©ÊÂùª¼Á{§É¡A´Á¤¤¸Ñª¼³ø§iªñ´Á±N¤½¥¬¼Æ¾Ú¡C ´Á¥½³ø§i¦~¤¤¤½¥¬¡C
¤T¡B2b约280¤H¡A¤µ¦~¤U¥b¦~¶}©l¡A约13Ó¤ë¥i§¹¦¨ªì¨B¼Æ¾Ú¡C2022¦~©³§¹¦¨¡C
¥|¡B¤T´Á须¤GÓ¤T´ÁÁ{§É¡A¦U400¤H¡A¦Xp800¤H¡A18Ӥ맹¦¨¥Dn¼Æ¾Ú¡C¦ô2024¦~©³§¹¦¨¡C
¤¡B2025¦~¶}©l¥Ó½ÐÃĵý¡A2016¦~¤¤/¤U¨úµý¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/7 ¤W¤È 08:20:27
²Ä 3636 ½g¦^À³
|
¨È狮¤½¥q²¤¶¤¤
P.21
³Ì¯à®i²{30»õ¬ü¤¸²{ª÷»ùÈ¡A´N¬O¸gÅçµýªºM0A§@¥Î¾÷Âà¸ô®|¦p¤U
Validated pathway: (¤wÅçÃÒªº¸ô®|¡K¡KMOA§@¥Î¾÷Âà)) Targets the same pathway and receptor complex (Type II) as dupilumab
(ASAN004¥Íª«»s¾¯¼Ð¹v¥Ø¼Ð©Mdupilumab¦³¬Û¦P¸ô®|¤Î«¬II½Æ¦X¨üÅé)
³Ì终结ªG¨Ï«¬II½Æ¦X¨üÅéµLªk组¦¨¡A¦Ó¦P®Éªý断¤¶¥Õ¯À4/13¸¹ªº°T®§¶Ç»¼¡A¦Óªý¤î«áÄòªº¹L±Óµoª¢¤ÏÀ³¡C
¸ô®|¤@¡B¥Ñ¤uL¤@4³y¦¨¹L±Óµoª¢¸ô®| (1)IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé)
¸ô®|¤G¡B ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé)
Dupilumab 结¦XIL-4R£\¡C ASLAN004 结¦XIL-13R£\1¡C
¨âºØ¤èªk¬Ò¥i¨ÏII«¬¨üÅéµLªk²Õ¦¨¡A¦ÓªýÂ_¹L±Ó¤Îµoª¢¤ÏÀ³¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/2/6 ¤U¤È 08:04:49
²Ä 3635 ½g¦^À³
|
ªÑ²¼³oªF¦è¡A¬O»ÝnÂI¹B®ðªº...·í®É·à¤lADS¤w¸g¬O·¸»ù¤F¡A¤£ºN¨â§â¤Ó¥i±¤... ¡]¨È·à±d16¤é¥xÆW¦¬½L»ù¬°7.96¤¸¡AADS¦¬½L»ù¬°1.85¬ü¤¸¡B§é¦X¥x¹ô¬ù¨CªÑ10.87¤¸¡A·¸»ù²v¬ù36.5%¡^
¶q¤O¦Ó¬°¡BÀH¾÷À³ÅÜ¡B¤×¨ä¬Oº©ªø±âÀߪº¥Í§ÞªÑ¡A §Ú²q«Ü¦h°µ¥Í§Þ¤j¹Úªº¡A³£¦³½ä®{©Ê®æ...«¢ ÁÙ¬Onµ¹¦Û¤v¯d°h¸ô¡B°µ¦n¸êª÷°t¤ñºÞ±±
¹w¯¬¤j®a·s¦~§Ö¼Ö¡A·à¤lµn®p¤j§q...LION KING
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/6 ¤U¤È 12:16:46
²Ä 3634 ½g¦^À³
|
¶i¤JªÑ¥«¯uªºn¨B¨B¬°Àç¡A¦p¼i Á¡¦B¡AnÅu¥¤]n§â®É¶¡©Ô±` Æ[¹î¡A§_«h´Nºâ¤d»õ¸êª÷¡A¤]·| ¥´¤ôº} ¯¬¤j®a¤Ï±Ñ¬°³Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2021/2/6 ¤W¤È 09:58:10
²Ä 3633 ½g¦^À³
|
·íªì¬O¬Ý¨ìª©¤W¦³¤H¤¶²Ð ¥[¤W¤jªÑªF¬O·s¥[©Y²H°¨¿ü ¦Û¤w¤S±q¨Æ·ÀIºÞ²z¦æ·~ ¬ã§P¦Ñ¦~¤ÆªÀ·|¤w¬O¤£¥i°f ¦]¦¹ÂåÃÄ Âå§÷ Âå¬ü«O°·¹«~µ¥¥«³õ¥i´Á ¤@¸ô±q42¼Ó©¹¤U·h ì¥H¬°¶R¨ì¤@°ï¾À¯È ¤£·Q³ºµMµ´³B³{¥Í «D±`·PÁª©¤W¦U¦ì¤j¤jµL¨p¤À¨É ·s¬K±N¦Ü ¯¬ªB¤ÍÌ~~~¤û¦~¤jµo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/2/6 ¤W¤È 09:41:55
²Ä 3632 ½g¦^À³
|
¤j¤á¤j¤j̳£ÀqÀqªº¦b¼ç¤ô «¢«¢
·Pı³Ìªñ¨È·à±d¤£¤Ó´M±` ¦n¨Æµo¥Í¶Ü?
ÁÂÁ¤ѩR¤jªº¤À¨É!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/6 ¤W¤È 08:34:24
²Ä 3631 ½g¦^À³
|
¯à¦Û°µASLAN004 --AD¤T´Á¤Î¦Û¾P,¦pREGN ¥Ñ¤p«¬ªÑ·sÃÄÅܤ¤«¬300~400»õ¬ü¤¸·sÃĪÑ,¦b¬üªÑADRÄw¸ê¾÷·|¤j.
¥[¤W²H°¨¿ü¤ÎÀq§J¨â¤j¦U2000»õ¬ü¤¸ªºªÑªFݸ³¨Æ,Âন¤¤«¬·sÃĪѾ÷·|§ó¤j.
---------------------------------------------------- §Ynªø§ë,°ò¥»¥\ÁÙ¬On½m,¹ý©³²z¸ÑAD MOA ·|Åý¤j®a§ó¦w¤ßªø©ê.
ªÑ»ù¦Û¤ÏÀ³¦b¦U¶¥¬q,¯à¨«¦h»·,¤@¤ÁÀH½t! ¬Ý¬Ý°ê»ÚAD±ÂÅv¤Î¨ÖÁÊ, ¥²¬O¤jÂצ¬!
1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù----
2017-2020¦~,¤w¾P°â70¦h»õ¬ü¤¸
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
3.Dupilumab MOA -¼v¤ù----¦³¤@¬qÅV¥Ü¤¶¥Õ¯À13 (IL13)ªº¦¨¥Î¾÷¨î,©MASLAN004 MOA -¼v¤ù¤@¼Ë.
4.MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
Lebrikizumab & Tralokinumab ¨âÃĪº¾÷Âà,¤]¦õµý¤FASLAN004 §@¥Î¦bIL-13 recepterªºÀu¶V.
¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G丶Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/6 ¤W¤È 08:32:08
²Ä 3630 ½g¦^À³
|
¥´¿ù¤F¡A¤£¬OPPT¡A¬OPTT¦³°Q½×¤å |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/6 ¤W¤È 08:23:37
²Ä 3629 ½g¦^À³
|
§Ú¤]¬O20´X¼Ó100±iªº¦í¤á ·à¤l¤jº¦³sPPT³£¦³¤Hª`·N¨ì¤F 観¬Ý¨ì¤@½g¨È·à±dªºµo¤åC ì¨ÓÁÙ¦³¤H°O±o³o®a¤½¥q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªÅÄ_10148533 |
µoªí®É¶¡:2021/2/6 ¤W¤È 07:56:58
²Ä 3628 ½g¦^À³
|
·s¦~§Ö¼Ö·à¤ÍÌ
·PÁ¤ѩR¤j¤jªºµL¨p¤À¨É ·PÁ¦U¦ì·à¤Í̪º¤¬¬Û¥´®ð
¥[ªo¹Æ ¡]42¼Ó129±iW¯º¤¤¡^ ì¥H¬°ÅܾÀ¯È¤F
·P®¦¨È·à±dªº°ª¼hÄ~Äò±a»â¤j®a §Æ±æÄ~Äò¦b¬ü°êµo¥úµo¼ö ³Ð³y»ùȹê²{¥Ø¼Ð
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/6 ¤W¤È 07:01:28
²Ä 3627 ½g¦^À³
|
¨È·à·à§q¡A·à¤Í̳£¿ô¤F...·s¦~§Ö¼Ö¦U¦ì¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2021/2/6 ¤W¤È 06:05:38
²Ä 3626 ½g¦^À³
|
¨û¨û¬O°µ¹L«Ü¦h¥\½Ò£x!
----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/16 ¤U¤È 11:37:50²Ä 1217 ½g¦^À³ ¸`¿ý¤½¥qºô¶ASLAN004ªº P1aµ²ªG»¡©ú...........- ---¤jP¸ò³o½g¾Ç²z¬ã¨s¦¨ªG§k¦X:www.ncbi.nlm.nih.gov/pmc/articles/PMC4553078/ (.DupilumabÂê©wIL-4R£\µ²¦X,ASLAN004Âê©wIL-13R£\1,³£¯àªýÂ_ IL-4 ¤Î IL-13, ¥u¬Oµ²ºc¾÷¨îªº±µ¦X¦¸§Ç¬Û¤Ï)
....These findings demonstrate that the IL-13R£\1 chain is required for signaling by IL-4 in fibroblasts but not in macrophages; however, in the case of IL-13, the IL-13R£\1 chain is essential for signaling by both macrophages and fibroblasts. Interestingly, we observed that the magnitude of STAT6 activation and gene expression induced by IL-4 in wild-type macrophages is generally greater than that induced by IL-13. These results are consistent with related findings by others [19, 20]
--------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/14 ¤W¤È 08:42:00²Ä 1194 ½g¦^À³ ASLAN004(IL-13R£\1)¦A¥[ºò¸}¨B,¨È·à±d«Ü¦³¾÷·|¦¨¬°COPDÅQ¥D!
1.2016ªº¤å³¹ www.nature.com/articles/mi201556 ....IL-13 receptor (R) £\1 and are key pharmacological
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2021/2/6 ¤W¤È 05:57:20
²Ä 3625 ½g¦^À³
|
Áà¤pÀn²×©óÅܤÑÃZÅo!
---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2019/12/1 ¤U¤È 12:45:32²Ä 1730 ½g¦^À³ §C»ù¤J¤â³q±`¦ñÀH«Ü°ª·ÀI¬O¨S¿ù,¦ý¦³®É¤§«áªº¶W°ª³ø¹S²v«o·|Åý¤H§ãµÃ¤£¤w!!! 10¦~«e³Ì¤j³Q°Ê¤¸¥ó¼t¬O«È¤á,3¤¸¥i¶R¨ì,¦p¤µ·Q·Q«Ü±{¹Ä! ·í®É§Ún¬O¦³¶R100¸U´N¦n,²{¦b¥i¶Rªk©Ô§Q.(¨º®É¶¢¿ú®³¥h¶R200¸U+¨®¤l¨É¨ü«C¬KOrz.)
----------------------------------------------------------------------------------------------- [·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/13 ¤U¤È 05:26:13²Ä 1190 ½g¦^À³ [..as well as results from our ASLAN004 .... Based on this exciting new data, we amended the agreement with CSL Limited to include full global rights to develop, manufacture, and commercialise this first in class therapeutic antibody for atopic dermatitis and other indications. ]®ÇÆ[¤w¤[,·Pı¥H¤W®×±¡¤£³æ¯Â,»ù¦ì±q64©¹¤Uªø¹F16Ó¤ë,À³¸Ó¬O°µ¹Ú³£·|¯º¿ôªº¾÷·|°ª¤@¨Ç! ¦~©³«e³°Äò¤½¥¬¤@¨ÇÁ{§Éµ²ªG,¤pÀ£¤â®ðÅo!]
-------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/28 ¤W¤È 09:43:04²Ä 1658 ½g¦^À³ °l·¥S¦pªG±z¶R¤J»ù¦b3.86¨º°÷µR§Q¤F! «¥Ã¨µ¥3¥H¤U¥[½X¤@¨Ç¦a....
[·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/11 ¤U¤È 04:33:19²Ä 1500 ½g¦^À³ ¥¢±Ñ¨Ã¤£¥i©È¡A¤ßºA¨M©w¤F§ÚÌ·|¦p¦ó¦^À³!§ë¸êµJÂI»P§ë¤J»ù¦ì¤£¦P¡A©Ò¯à©Ó¨üÀ£¤O´N¤£¤@P¡C «¥10¶ôªì§ë¤J¡A¬OÀ£µ¥«½SÃĪ«ASLAN004½µP!©ó«¥¨Ó»¡¡A©ú¦~¤~¬O¨£¯u³¹Â_¥Í¦º®É¨è¡C]
·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/23 ¤W¤È 05:56:39²Ä 1602 ½g¦^À³ ¥un¤U¥«·ÀI¸Ñ°£,«¥·|¦ø¾÷¥[½XÅu¥! µ¥«Ý¥X²{ÄéÄx°ª¤âªº¬y¤t·¬»PÄå¤ìªá¹D(003/004),´Nºâ³Ì«á¤@¨è¤]¯à¤Ï±Ñ¬°³Ó!!!
[·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/13 ¤U¤È 03:44:08²Ä 1541 ½g¦^À³ ¦¨¥»12¤¸!
[·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/11 ¤U¤È 04:33:19²Ä 1500 ½g¦^À³ ¥¢±Ñ¨Ã¤£¥i©È¡A¤ßºA¨M©w¤F§ÚÌ·|¦p¦ó¦^À³!§ë¸êµJÂI»P§ë¤J»ù¦ì¤£¦P¡A©Ò¯à©Ó¨üÀ£¤O´N¤£¤@P¡C «¥10¶ôªì§ë¤J¡A¬OÀ£µ¥«½SÃĪ«ASLAN004½µP!©ó«¥¨Ó»¡¡A©ú¦~¤~¬O¨£¯u³¹Â_¥Í¦º®É¨è¡C] ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/11/13 ¤U¤È 03:37:28²Ä 1540 ½g¦^À³ ¦n©_½Ð°ÝROGER5889¤j ©M¤Ñ©R¤j §A̤â¤WÁÙ«ù¦³¨È·àªÑ²¼¶Ü? ¦pªG¦³¡AªÑ»ù¶^¨ì²{¦b¡A¦p¦¹¯ëªº¥¿±«ä¦Ò¡A¥O¤H´Ü¨Ø! ]
·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/13 ¤U¤È 02:49:13²Ä 1539 ½g¦^À³ ASLAN004»PDupilumab¨ì©³¨º¤@¤ä¤~¬O¥Ì½©ËµÛ¦Y·|¶V¨Ó¶V²¢!? ©ú¦~§Y¨£¯u³¹¡C
·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/11 ¤U¤È 10:51:03²Ä 1517 ½g¦^À³ §ë¸ê§O¤£©ú¨s²z¸òÀH¨ä¥L¤H¨B¥ï! »`¶°¸ê®Æ«á,¸g¹L¦Û¤vÅçÃÒ«ä¦Òªº¸ê°T¤~¯u¥¿ÄÝ©ó¦Û¤v©Ò¦³. ©ú¦~004¼Æ¾Ú¦p¹w´Á,¨º»ò¨È·à±d±N±qÁà¤pÀnÅܤÑÃZ!
[·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/11/11 ¤U¤È 09:54:28²Ä 1516 ½g¦^À³ ¬Ý¥²´I§ë¸ê¥_·¥¬PÅý§ÚÁȤF100¸U¬Ý¥²´I§ë¸ê¨È·à±dÅý§Ú½ß¦^¥hÁÙ˶K(50±i§¡»ù43¦h)----]
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2021/2/6 ¤W¤È 05:49:12
²Ä 3624 ½g¦^À³
|
¦³¤H«Ü·Q§Ú??????? ´±¦M¾÷¤J¥«5¤¸¶R¤J¡A Áx¤j¤ß²Ó¡A±z§Y±N·|ÁȽ!!! ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/5/8 ¤W¤È 10:13:24²Ä 2530 ½g¦^À³ ³oÓ»ù¦ì±þµL¦×¡A±ó¤§¥i±¤! Á«¬O¤@¿,ÁÈ«h¬O´X¤Q¿¬Æ¦Ü¦Ê¿. ºÝ¬Ý004¬O¤£¬O¦n°sÅo!? -------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2020/6/18 ¤W¤È 08:31:35²Ä 2755 ½g¦^À³ ¥Õ®ö·Ê·Ê§Ú¤£©È;´I¶Q¥»¬OÀI¤¤¨D. ........................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/5/8 ¤W¤È 10:41:11²Ä 2532 ½g¦^À³ Ãø«O³oÓ¦ÑÁ󤣷|¤]¥X¤U¥«³oºØ¶ø¨B? ´¦¶}³¯®õ»Ê±N°ê¥¨¤U¥«¤º¹õ¡þ¤j¦ÑÁ󪺳¥ÆZª÷¿ú¹CÀ¸ stock.pchome.com.tw/magazine/report/po/businesstoday/4299/130262400027479004001.htm
............................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/4/20 ¤W¤È 08:24:11²Ä 2469 ½g¦^À³ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/20 ¤W¤È 07:34:49²Ä 2468 ½g¦^À³ ¥xÆW¤U¥«¤£¥NªíASLAN004 ´N¬OªÅ¡C .......................................................................... ¨S¿ù+1 2018Áp¥Ín¤U¥«,¤½¥q¬£25¤¸¦¬,¶^¨ì20¤¸¤§¤U,²V¤ô¤¤«¥ºN¤F´X±ø³½! ¤£¹L¦b2019-04/18Áp¥ÍÃĪvÀø·R´þ¯f§ÜÅé·sÃÄUB-421Á{§ÉII´Á¸ÕÅçµ²ªG ºaÀò¥Zµn©ó·s^®æÄõÂå¾Ç´Á¥Z«á, «¥·P¨ì«á®¬¤Ï¦ÓnÄ~Äò«ù¦³! www.unitedbiopharma.com/tw/news_detail.php?id=251
¥tÃþ«ä¦Ò: ´¦¶}³¯®õ»Ê±N°ê¥¨¤U¥«¤º¹õ¡þ¤j¦ÑÁ󪺳¥ÆZª÷¿ú¹CÀ¸ stock.pchome.com.tw/magazine/report/po/businesstoday/4299/130262400027479004001.htm ..........................................................................................
·|û¡GROGER588910148151 µoªí®É¶¡:2020/5/8 ¤W¤È 10:52:39²Ä 2533 ½g¦^À³ ¯à²q³z¦ÑÁ󪺫äºû?
2019-12-03 05:30 ¤O´¹¶°¹Î¸³¨Æªø¶À±R¤¯¡]¥k¡^¹wp©ú¦~¥H¤O¿n¹q¤§¦W¥Ó½Ðµn¿ý¿³Âd¡A³W¹º«·s¤W¥« ¡C ec.ltn.com.tw/article/paper/1336373 ....... ¤O´¹2012¦~´¿¤j´T´î¸ê¡A¤@¨Ç´î¸ê«á¥H§C»ù¤j¶R¤O´¹ªº¤pªÑªF¡A¤£¥F«ù¦³¤W¸U©Î´X¤d±i¡Aªñ´X¦~»â¨ìªºªÑ§Q§¡¤Q¤ÀÅå¤H¡C¤£¹L¡A¤]¦³¤U¥««e©Î´î¸ê«e«ù¦³ªº¤pªÑªF¡AºG½ß¦Ü¤µ¡A´Á±æ¤O´¹¥H¤O¿n¹q¤§¦W¦¤é«ªð¤W¥«¤§¸ô¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/5 ¤W¤È 11:00:26
²Ä 3623 ½g¦^À³
|
¤ª¦ó°¥ñ¨ä¤ß¡H
À³µL©Ò¦í¦Ó¥Í¨ä¤ß¡I<ª÷è¸g>
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/5 ¤W¤È 10:38:38
²Ä 3622 ½g¦^À³
|
«ö¤Ñ©R¤jªº¤ÀªR¡A³Ì°ª»ùȪº¸ôÁ٫ܺCªø ©O¡I¤¤¶¡¦³¤Ó¦h¤£½T©w¦]¯À ½Ö¤~¬O³Ì²×ªºÄ¹®aÁÙ¥¼ª¾©O µ¥¦^¥»¬O·Î¼õ¡A¶}©lÀò§Q¤]¬O·Î¼õ ¹Lµ{«Ü¦h·|¤U¨®¨S³o»ò®e©öªº ³£¬O©R°Ú¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/5 ¤W¤È 09:07:35
²Ä 3621 ½g¦^À³
|
¶P¨È·à¨ÌÂÂéw¤W´¡A·íªì¶R¨È·à¤]¬O¬Ý¤W©Ò¦³¥¿¦V¼Æ¾Ú¡A¶R¶iªº¨C¤@¤Ñ³£²ßºD¤W³o°Q½×°Ï¡AÁ`¬O§Æ±æ¬Ý¨ì¨Ç¤°»òµ¹¦Û¤v«H¤ß¡A³o´Á¶¡«Ü¦h¤H³£¬O40¦h¶}©l©¹¤U¶R¡A¦b5¶ô¿ú¥ª¥k¶i³õªº¬°¤§¤Ö¼Æ¡A¤§«e¦³¦ì¤j¤j(§Ú§Ñ¤F¬O½Ö)¦b12¶ô¥ª¥k¹ªÀy¤j®a¶R¶i¡A¥L»¡¤é«á¤@©w¤£t²³±æ¡A¥H²{¦b»ù®æ¨Ó¬Ý¡AÀ³¸Ó¤w¸g¶}©lÀò§Q¡A¤j¦h¼Æ·à¤ÍÌÀ³¸Ó§¡»ù¸¨¦b¥x¹ô25¤W¤U(µ²¦X¨ä¥L°Q½×°Ï°T®§)¡A®¥³ß¤w¸gÀò§Qªº·à¤Í¡A±b±ÁÙ¦bÁ«·lªº·à¤Í¤]§O¹Ä®§¡A²{¦bªº¦U¶µ¼Æ¾Ú¥]§t§Þ³N±½u«¬¡A¨ä¹ê³£«Ü´Î!¤ë¡B¶g¡B¤é©Ò¦³§¡½u³£¯¸¤W¡Aªí²{¯uªº«ü¤é¥i«Ý!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/4 ¤U¤È 09:02:24
²Ä 3620 ½g¦^À³
|
¶}¥X¬°¦³ ¥Ü¥X¬°µL ®©µL¦³µL ¤J¥XµLê
¦ò¥X¥@¤§¤@¤j¦]½t :
¶}¡B¥Ü¡B®©¡B¤J ½t°_¡B©ÊªÅ¤§¯ëY´¼¼z |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/2/4 ¤U¤È 08:48:19
²Ä 3619 ½g¦^À³
|
YµÐÂĤߤ£¦íªk¦Ó¦æ¥¬¬I¡A¦p¤H¦³¥Ø¡A¤é¥ú©ú·Ó¡A¨£ºØºØ¦â¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/4 ¤U¤È 08:25:59
²Ä 3618 ½g¦^À³
|
ª÷è¸g¤j´¼¼z ¦òªk¤~¬Oâ¾r¥@¶¡¤@¤Áªkªº¤jÄ_Âà |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/2/4 ¤U¤È 07:44:26
²Ä 3617 ½g¦^À³
|
¤§«eµo²{¤pS¤½¤½¤]¦³¶Rasln ¦b4¤¸¦hªº®É«á |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/2/4 ¤U¤È 07:35:32
²Ä 3616 ½g¦^À³
|
«z ì¨Ó³o¦³¦b°Q½× ¨È·à±d ¯uªº¤Ó¦n¤F ·íªìnÂà®É Àç·~û¤@°Ý¤T¤£ª¾ ¤f®ð¤S¶W®tªº ¥s§Ú½æ¤@½æ´N¦n¤F ¦ý...§Ú¤]¬O¦¨¥»«Ü°ª ©êµÛ³Ì«á§Æ±æ Âà¬üªÑ ¨C¤Ñ·|Ãö¤ß ·à ¤@¤U «e´X¤Ñµo²{Àþ¶¡º¦¤T¤Q´X%º¡¿³¾Äªº ÁöµM³Ì«á¤S¦^¶^... §Æ±æ±µ¤U¨Ó³£¦³¦n®ø®§ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/4 ¤U¤È 06:03:06
²Ä 3615 ½g¦^À³
|
youtu.be/_gveT-SqjrE
ª÷è¸g¤Q¤j¸g¥y,¥y¥y¬Ò¥i¥O¤H¶}®©¡A¬Ò¥i©ú¤ß¨£©Ê
¥H¦p¨ÓÂÃ(Âæp¨Ó)¸ÑÄÀª÷è¸g¤Q¤j¸g¥y¡A¸ÑÄÀªº«D±`¨ì¦ì¡C
01:08 ²Ä¤@¥y ¤Z©Ò¦³¬Û¡A¬Ò¬Oµê¦k¡CY¨£½Ñ¬Û«D¬Û¡A§Y¨£¦p¨Ó¡C 03:00 ²Ä¤G¥y ¤@¤Á¦³¬°ªk¡A¦p¹Ú¤Ûªw¼v¡C¦pÅS¥ç¦p¹q¡AÀ³°µ¦p¬OÆ[¡C 04:01 ²Ä¤T¥y ªk©|À³±Ë¡A¦óªp«Dªk¡C 05:01 ±a¥|¥y ©Ò¿×¦òªkªÌ¡A§Y«D¦òªk¡C 05:36 ²Ä¤¥y À³µL©Ò¦í¦Ó¥Í¨ä¤ß¡C 06:44 ²Ä¤»¥y YµÐÂĦ³§Ú¬Û¡A¤H¬Û¡A²³¥Í¬Û¡A¹ØªÌ¬Û¡A§Y«DµÐ蕯¡C 07:42 ²Ä¤C¥y ¹L¥h¤ß¤£¥i±o¡A²{¦b¤ß¤£¥i±o¡A¥¼¨Ó¤ß¤£¥i±o¡C 08:20 ²Ä¤K¥y ¬Oªk¥µ¥¡AµL¦³°ª¤U¡C 09:17 ²Ä¤E¥y ©Ò°µºÖ¼w¡A¤£À³³gµÛ¡C 10:07 ²Ä¤Q¥y ¦p¨ÓªÌ¡AµL©Ò±q¨Ó¡A¥çµL©Ò¥h¡A¬G¦W¦p¨Ó¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/4 ¤U¤È 04:11:56
²Ä 3614 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/4 ¤U¤È 03:59:17
²Ä 3613 ½g¦^À³
|
§d½n¶¯¤j§A¶R¦b5¤¸¡A²{¦b´NÁȨ⿤F ²{¦bADS´«ºâ°_¨Ó¬ù¥xªÑ15¶ô¦h(¶×²v¥Î28ºâ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/2/4 ¤U¤È 03:51:35
²Ä 3612 ½g¦^À³
|
¦b·à¤l³Ñ5¤¸¸õ¼Ó¤j©ç½æªì¦¸±µ¤âªº¡A¶]¤F¤T®a»È¦æ¤~Âনadr¡A¦³¿ú´N¸Éadr...
»¡¯uªº¡A·PÁ¤ѩR¤j¡A¦hÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/4 ¤U¤È 02:15:05
²Ä 3611 ½g¦^À³
|
youtu.be/03I4u6wo_lY
¡Õ¤»¯ª¾Â¸g¡Ö
µÐ´£¦Û©Ê¡A¥»¨Ó²M²b¡C¦ý¥Î¦¹¤ß¡Aª½¤F¦¨¦ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/4 ¤U¤È 02:00:49
²Ä 3610 ½g¦^À³
|
¤@¤ÁÀH½t!
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X
·PÁ¦ѤѡA¦]§ë¸ê¦Ó»{ÃÑ¡§ÁI¡¨¡A¸Uªk¬ÒªÅ©ú¦ò©Ê¡A¤@µ·𣎴±¾ÃÒðÕ¤ß!
¹y®©: ®©µL©Ò±o¡A¾·°£¦k©À¡X¡X¡X¡Õ¤j³q©M©|¡Ö
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤@¤Á¦³¬°ªk¡A¦p¹Ú¤Ûªw¼v¡A¦pÅS¥ç¦p¹q¡AÀ³°µ¦p¬OÆ[¡Õª÷è¸g¡Ö
¤@¤Á
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2021/2/4 ¤U¤È 01:30:43
²Ä 3609 ½g¦^À³
|
³o¤@¸ô¨«¨Ó·PÁÂ¥]¬A¤Ñ©R¤jµ¥½Ñ¦ì¤j¤jªº¤ÀªR»P¤À¨É ¤]²`¨è·P¨ü·à¤l¤½¥q°ª¼h¹ï¤pªÑªFªº·ÓÅU ³QªB¤Í̳£Â_©w¦¨¾À¯ÈªºªÑ²¼©~µM°_¦º¦^¥Í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/4 ¤U¤È 12:50:15
²Ä 3608 ½g¦^À³
|
ÁÙ¦n¦³¤Ñ©R¤j±M·~ºë·Çªº¤ÀªR¡A¶i°h¤§¶¡ ¯à¦³©Ò®³®º ¤@¸ô¨«¨Ó¤]¦ü¥G«ö·Ó¤Ñ©R¤jªº¤ÀªR¥Ø¼Ð«e¶i¡A ¤F¸Ñ¨ì¾Þ§@ªÑ²¼±M·~ªº«n¡A¨ü¯qê²L ·P®¦ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/4 ¤W¤È 11:07:42
²Ä 3607 ½g¦^À³
|
¦N¦Ì¤j»¡ªº¨S¿ù §Ú¤]»{¬°¯d¦b¥xªÑ¤@©w«ÜºG ·íªì¦b¥x¤U¥«nÂà¬üªÑ®É «Ü¦hºô¤Í¬Ý°I°S¯º¡A§Ú©l²×»{¬°³o¤~¬O¹ïªº¸ô ÁöµMÂà´«¹Lµ{¦³°÷³Â·Ð®`¤j®a¶]¦n´X¦¸»È¦æ ¦ý¬Û«H¤j®a³Ì«á³£¯à±o¨ì¬ü¦n¦¨ªG
¥[ªo¤F¡A¥ý¯¬ºÖ·à¤Í®¥³ßµo°]¡B·s¬K´r§Ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/4 ¤W¤È 09:46:41
²Ä 3606 ½g¦^À³
|
¨È·àéw¤W´(2.7)¡A¯u¬O¤£¿ù!!¦^ÀY¬Ý¥xªÑ¡AÁöµM¤W16000¡A¨ä¹ê«Ü¦hªÑ²¼³£«ÜºG¡A¨È·à¦pªGÄ~Äò¯d¦b¥xªÑ¡A·Q¥²¤]¬O«ÜºG!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/3 ¤U¤È 12:04:52
²Ä 3605 ½g¦^À³
|
REGNªÑ»ù2011¦~©³«e³QÀ£§í¬O¦]¬° Lucentis(²Ä¤@¤W¥«黄´³³¡¯fÅÜ°w¾¯)¦b2011¦~¶È¾P22»õ¬ü¤¸¥ª¥k¡C
¡K¡K¡K¡K¡K¡K¡K¡K
REGNªº Eylea ¤W¥««á¡A°»ù¦Ü¹ï¤âªºLucentis66.6%,¥«³õ¾P°âÂX¥R76»õ¬ü¤¸¡AÂX¥R²v176%. ¥«Ô·º¯³z²v(¤H¼Æ)ÂX¥R265%,(176%/66.6%=265%)
2015 Lucentis ³Ì°ª¾P°â43»õ¬ü¤¸ 2019¦~ ¨âÃľP°â¦Xp119»õ¬ü¤¸
¨ì2019¦~¥«³õ¼W¥[119-43=76»õ¬ü¤¸
76/43=176% ¼W¥[²v.-----(¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº)
2012: Eylea ¤W¥«²Ä¤@¦~¾P°â¬°Lucentis¤w¤W¥«6¦~ 36%. 2013: Eylea ¤W¥«²Ä¤G¦~¾P°â¬°Lucentis¤w¤W¥«7¦~ 51%. 2014: Eylea ¤W¥«²Ä¤T¦~¾P°â¬°Lucentis¤w¤W¥«8¦~ 65%. 2015: Eylea ¤W¥«²Ä¥|¦~¾P°â¬°Lucentis¤w¤W¥«9¦~ 120%.
2012 ¨âÃľP°â¦Xp32.7»õ¬ü¤¸ 2013 ¨âÃľP°â¦Xp50.96»õ¬ü¤¸ 2015 ¨âÃľP°â¦Xp74.8»õ¬ü¤¸ 2016 ¨âÃľP°â¦Xp88.38»õ¬ü¤¸ 2019 ¨âÃľP°â¦Xp119»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=181%**104 2019¡V41(¦ô)//78.52**B/A=191%**119
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î
¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C
Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/3 ¤W¤È 11:40:14
²Ä 3604 ½g¦^À³
|
finance.yahoo.com/quote/regn ¯u¥¿¨«REGNªº¥i¯à©Ê¡A¬O¨È·àASLN
2011¦~©³¡AFDA®ÖãÃÄ©w ¤W¥«ªv黄´³³¡¯fÅÜ°w¾¯ 2020¦~¦ô销约70»õ¬ü¤¸
2017¦~3¤ë¡AFDA¡A®ÖãDupilumab¤W¥« ªÑ»ù¬Ò´£«e¤ÏÀ³¡C
2020¦~¦ô¾P40»õ¬ü¤¸ 2021¦~¦ô销58»õ¬ü¤¸ ¥¼¨Ó100»õ欧¤¸¾P°â
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/3 ¤W¤È 11:24:04
²Ä 3603 ½g¦^À³
|
¨È狮³Ì°ª»ùȦb¦Û°µ¤T´Á¡A¦Û¦æ¾P°â
¯à¨«¦h»·¡H随顺¦]½t¡I
¨È·à ¥¼¨Ó¥«È/ADRªÑ»ù¤§¹w¦ô
1.2021¦~7¤ë°µ§¹ASLAN004 1b ADÁ{§É, ¨È·à³QÁʲ{ª÷»ùÈ: 30»õ¬ü¤¸ ADR 54¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ> ---Y¥[ASLAN003(2b MSÁ{§É¶}©l) 5»õ¬ü¤¸, ¨È·à³QÁʲ{ª÷»ùÈ: 35»õ¬ü¤¸----- ADR 63¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
2.2022¦~12¤ë°µ§¹ASLAN004 2b ADÁ{§É, µ²ªG¦p¹w´Á ¨È·à³QÁʲ{ª÷»ùÈ: 35»õ¬ü¤¸ ADR 63¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
---Y¥[ASLAN003(2b MSÁ{§É§¹¦¨) 7»õ¬ü¤¸, ¨È·à³QÁʲ{ª÷»ùÈ: 42»õ¬ü¤¸----- ADR 75¬ü¤¸/ªÑ---¸ê¥»ÃB56,000¤dªÑ>
3.2024¦~12¤ë°µ§¹ASLAN004 3´Á ADÁ{§É µ²ªG¦p¹w´Á, ¨È·àADR ¥«È60»õ¬ü¤¸´Á±æÈ ADR 90¬ü¤¸/ªÑ---¸ê¥»ÃB67,000¤dªÑ>
---Y¥[ASLAN003(2b MSÁ{§É§¹¦¨) 7»õ¬ü¤¸, ¨È·àADR ¥«È: 67»õ¬ü¤¸----- ADR 100¬ü¤¸/ªÑ---¸ê¥»ÃB67,000¤dªÑ>
4.2026¦~3¤ë¤W¥« 3Ó¤ë,¦Û¤v¾P°â , ¨È·àADR ¥«È150»õ¬ü¤¸´Á±æÈ/¥¼¨Ó¾P°â¨ì60»õ¬ü¤¸
ADR 180¬ü¤¸/ªÑ---¸ê¥»ÃB80,000¤dªÑ> ---¥¼¦ôASLAN003»ùÈ
5.2026¦~12¤ë ~2027¦~,¤W¥«¾P°â¶W¶V¹w´Á,´£°ª¥¼¨Ó¾P°â¨ì100»õ¬ü¤¸
¨È·àADR ¥«È250»õ¬ü¤¸´Á±æÈ ADR 300¬ü¤¸/ªÑ-¸ê¥»ÃB80,000¤dªÑ> ---¥¼¦ôASLAN003»ùÈ
----------------------- (ASLAN003 2b MS Á{§É§¹¦¨, ¬ù10»õ¬ü¤¸¾P°â/7»õ¬ü¤¸§é²{¼çÈ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/3 ¤W¤È 08:51:48
²Ä 3602 ½g¦^À³
|
ÁöµM3¶ô¥u¦³¤@¤U¤U¡AÓ¤Hı±oÀ³¸Ó¬O¦³¨Ç¤H¡A¤w¦^¨ì¦¨¥»»ù¡A¥ý½æ¥X¸¨³U¡A²¦³ºµ¥«Ü¤[¤F¡A¦ý¨S½æ¥Xªº¤H¡A´N¬O´Á«Ý¨È·àªº¤jÃzµo¡A¦U¶µ¼Æ¾Ú³£¬O¥¿¦Vªº¡A°í«ù¤@©w·|¦³¦nªº¤ÏõX¡A¤j®a¥[ªo! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/3 ¤W¤È 08:02:21
²Ä 3601 ½g¦^À³
|
³Ì¤jªÑªF·s¥[©Y°]¬F³¡/Merck, ¦WÁn>ªk«ß>¨p§Q CEO ³ÅÁ` 3300±i¥xªÑ+¥¼¨Ó»{ªÑÅv, ¥xªÑÂàADR¨ä§Q¯q³Ì¤j ¨ì¬ü°ê¸ê¥»¥«³õ¤ñ¥xÆW¤j¦Ê¿¡A¥Í§Þ§ë¸ê¾÷ºc¦h¥B±M·~
¦b¬ü°ê¤W¥«,Y¦³¹HªÑªF§Q¯q, «ß®v¨Æ°È©ÒÌ ·|¥D°Ê¥X¨Ó¥´©x¥q¬°¤pªÑªF¨DÀv¦Ó¤À§Q¼í.
----------------------------- ¨È·à±d§ó¬O¥xÆW¤¤¤Ö¼Æ¨ã¦³°ê»Ú¤j¼t»P¥ý¶i°ê®a¬F©²¤ä«ùªº·sÃĶ}µo¤½¥q¡AªÑªF¥]¬AMerck(ªÑÅv¦û¤ñ7%)¡B·s¥[©Y²H°¨¿ü°òª÷(ªÑÅv¦û¤ñ6%)¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/3 ¤W¤È 07:45:52
²Ä 3600 ½g¦^À³
|
½T¹ê¦p¬õ¹Ð¤j©Ò»¡ ©Ò¥H·à¤lÄ@·N¨ó§UÂà´«¯uªº«Ü¦³¸Û·N »¡¨ì¦Ñ·à¤Í¡A§ÚÁÙÆZ·Q©À¸¤H¥d¯S¤j¤j ¤£ª¾¸¤H¤j¬O§_ÁÙ¦³«ùªÑ¡AÁÙ¬O¤w¸g©ñ±óÂ÷¶}¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/3 ¤W¤È 07:22:12
²Ä 3599 ½g¦^À³
|
¨ä¹ê·íªì¥xÅs¤U¥«®É¡A ¤½¥q§â©Ò¦³ªº¥xÅsªÑ¥÷ §]¤F¡A¦Ñ·à¤ÍÌ¥i¯à¥u¦³ »ó¤lºN¤@ºN¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/3 ¤W¤È 07:06:19
²Ä 3598 ½g¦^À³
|
¤@¶¡¤½¥q¬O§_ȱoªø´Á§ë¸ê¡A¨Mµ¦°ª¼h ªº¸Û«H¡A¬O¤ñµu´ÁªºÀç¹Bª¬ªp«nªº¦h¡A ·íªìn¬O¦A¥xÅsª½±µ¤U¥«¡A©Î³Q´c·N¨Ö§]¡A ´N¨S¦³¥Ø«e³oÓª©¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/2 ¤U¤È 11:26:27
²Ä 3597 ½g¦^À³
|
¤½¥q1.5»õ¬ü¤¸¶Ò¸ên¦¨¥\, ¥Ø¼Ð»ùadr ¨CªÑ21¬ü¤¸¥H¤W
³Ì°ªµo¦æ¶q¶È7152¤dªÑADR |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2021/2/2 ¤U¤È 11:23:56
²Ä 3596 ½g¦^À³
|
®¥³ß¤j®aÌ, ÂM·à²×©óºÎ¿ô, 3¤¸¹F¼Ð. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/2 ¤U¤È 11:13:53
²Ä 3595 ½g¦^À³
|
¬ü°ê¥i¼W¸êªk«ß:
®Ú¾Ú³q¥Î»¡©úI.B.5¡C®Ú¾ÚF-3ªí®æªº³W©w¡A¦b¥ô¦ó±¡ªp¤U¡A¥un§Ú̪º¤½²³«ùªÑ¶q¦b¥ô¦ó12Ӥ뤺¡A§Ú̳£¤£·|¥X°â¨ä¦b¥»©ÛªÑ»¡©ú®Ñ¸É½s¤¤¥]§t¦b¨äµn°OÁn©ú¤¤ªºÃÒ¨é¡A¨ä»ùȶW¹L¤½²³«ùªÑ¶qªº¤T¤À¤§¤@¥H¤W¡C
¤@.2019¦~ 12¤ë2¤é®Ú¾Ú³q¥Î»¡©úI.B.5¡C®Ú¾ÚF-3ªí®æªº³W©w¡A¦b¥ô¦ó±¡ªp¤U¡A¥un§Ú̪º¤½²³«ùªÑ¶q¦b¥ô¦ó12Ӥ뤺¡A§Ú̳£¤£·|¥X°â¨ä¦b¥»©ÛªÑ»¡©ú®Ñ¸É½s¤¤¥]§t¦b¨äµn°OÁn©ú¤¤ªºÃÒ¨é¡A¨ä»ùȶW¹L¤½²³«ùªÑ¶qªº¤T¤À¤§¤@¥H¤W¡C «DÃöÁp¤½¥q«ù¦³ªº¬y³q¦b¥~´¶³qªÑªºÁ`¥«È¬ù¬°4420¸U¬ü¤¸¡A³o¬O®Ú¾Ú«DÃöÁp¤½¥q«ù¦³ªº137,656,709ªÑ´¶³qªÑ©M¨CªÑ·s¥x¹ô9.95¤¸ªº»ù®æpºâ±o¥Xªº¡C TPEx¬°2019¦~10¤ë3¤é¡A©Î¨CªÑ0.321¬ü¤¸¡A°ò©ó¸Ó¤é´Á·s¥x¹ô30.99¤¸§I1.00¬ü¤¸ªº¶×²vpºâ¡C
160,489 ¤dªÑ/ ¥xªÑµo¦æ¶q - 137,656¤dªÑ/«DÃöÁp¤½¥q«ù¦³=22,833¤dªÑ/ÃöÁp¤½¥q«ù¦³
¤G.2019¦~12¤ë¼W¸ê«áªÑ¥»189,955¤dªÑ(¥xªÑ)
¤T.2020¦~12¤ë¼W¸ê3326¤dªÑADR 180,000/5=36,000¤dªÑ ADR+
¦©°£ 22,833¤dªÑ/ÃöÁp¤½¥q«ù¦³
22833/5=4566 ¤dªÑ ADR/ÃöÁp¤½¥q«ù¦³
36,000-4566=31,434 ¤dªÑ ADR/«DÃöÁp¤½¥q«ù¦³
31434/3=10,478 ¤dªÑ¥iµo¦æ-----2020¦~©³ ¥|.¥Ø«e¥iµo¦æ
10478-3326(2020/12¤ë¤wµo¦æ)=7,152 ¤dªÑ ADR ¥iµo¦æ
150,000,000/7152000=21 ¬ü¤¸/ADR
Äw¸ê¦¨¥\¬üª÷1.5»õ, ³Ì°ª¥iµo¦æ¶q7152 ¤dªÑ ADR,¨CªÑ21¤¸³Ì§C»ù®æ
7152/(36,000+3326)=18.19%
------------------------------------------ www.sec.gov/Archives/edgar/data/1722926/000119312519304462/d842091d424b5.htm
dated December 2, 2019
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated November 8, 2019) §ÚÌ´£¨Ñ¬ü°ê¦s°UªÑ²¼¡]ADS¡^¡C¨C¥÷¬ü°ê¦s°U¾ÌÃÒ¥Nªí¤ªÑ´¶³qªÑ¡A¨Ã¥Ñ¬ü°ê¦s°U¾ÌÃÒ¡]ADR¡^ÃÒ©ú¡C
§Ú̪º¬ü°ê¦s°U¾ÌÃÒ¦b¯Ç´µ¹F§J¥þ²y¥«³õ¤W¥H¡§ ASLN¡¨ªº¥N½X¦C¥X¡C 2019¦~11¤ë29¤é¡A§Ú̦b¬ü°ê¯Ç´µ¹F§J¥þ²y¥«³õ¤Wµo¥¬ªº¬ü°ê¦s°U¾ÌÃÒ¡]ADS¡^ªº³Ì·s³ø¥X»ù®æ¬°¨C¥÷ADS 3.82¬ü¤¸¡C§Ú̪º´¶³qªÑ¦b¥x¥_ÃÒ¨é¥æ©ö©Ò¡]TPEx¡^¤W¥«¡C®Ú¾Ú·s¥x¹ô30.53¤¸¹ï1.00¬ü¤¸ªº¶×²v¡A§Ú̦b2019¦~11¤ë29¤éµo¥¬ªº´¶³qªÑ³Ì·s¥X°â»ù®æ¬°¨CªÑ·s¥x¹ô6.32¤¸¡A¬ù¦X¨CªÑ0.21¬ü¤¸¡C
«DÃöÁp¤½¥q«ù¦³ªº¬y³q¦b¥~´¶³qªÑªºÁ`¥«È¬ù¬°4420¸U¬ü¤¸¡A³o¬O®Ú¾Ú«DÃöÁp¤½¥q«ù¦³ªº137,656,709ªÑ´¶³qªÑ©M¨CªÑ·s¥x¹ô9.95¤¸ªº»ù®æpºâ±o¥Xªº¡C TPEx¬°2019¦~10¤ë3¤é¡A©Î¨CªÑ0.321¬ü¤¸¡A°ò©ó¸Ó¤é´Á·s¥x¹ô30.99¤¸§I1.00¬ü¤¸ªº¶×²vpºâ¡C§ÚÌ©|¥¼®Ú¾Ú³q¥Î»¡©úI.B.5´£¨Ñ¥ô¦óÃÒ¨é¡C¦bºI¦Ü¥»©ÛªÑ»¡©ú®Ñ¼W¸É¤é¡]¥]¬A¸Ó¤é¡^ªº«e12Ó¤é¾ä¤ë¤º¶ñ¼gF-3ªí®æ¡C¬y³q¶q¤´§C©ó7500¸U¬ü¤¸
dated December 2, 2019
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated November 8, 2019)
American Depositary Shares
LOGO
Representing Ordinary Shares
We are offering American Depositary Shares, or ADSs. Each ADS represents five ordinary shares and will be evidenced by American Depositary Receipts, or ADRs.
Our ADSs are listed on The Nasdaq Global Market under the symbol ¡§ASLN.¡¨ On November 29, 2019, the last reported sale price of our ADSs on The Nasdaq Global Market was $3.82 per ADS. Our ordinary shares are listed on the Taipei Exchange, or TPEx. The last reported sale price of our ordinary shares on November 29, 2019 was NT$6.32 per share, or approximately $0.21 per share, based on an exchange rate of NT$30.53 to $1.00.
The aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, was approximately $44.2 million, which was calculated based on 137,656,709 ordinary shares outstanding held by non-affiliates and a per share price of NT$9.95 as reported on the TPEx on October 3, 2019, or approximately $0.321 per share based on an exchange rate of NT$30.99 to $1.00 on such date. We have not offered any securities pursuant to General Instruction I.B.5. of Form F-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus supplement. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell securities registered on the registration statement of which this prospectus supplement is a part with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75 million.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/2 ¤U¤È 10:53:00
²Ä 3594 ½g¦^À³
|
¨S·Q¨ì³st¤j¤]¬Ý¦h¤F ¯u¤ß§Æ±æ·à¤l¤£nÅý¤j®a¥¢±æ ÁÙ°O±o·à¤l¦b¥x¤W¥«¨ì¤U¥« GÀùÁx¹DÀù±µ³s¥¢±Ñ ³Q¤£©ú¨s²zªººô¤Í»ÄÃz¬O¨Ó¥xÄF¿úªº¤½¥q ¦ý±q¥¦Ä@·N¨ó§U¥xÆW§ë¸ê¤HÂà´«ADR®É §Ú´NÄ@·N¦A¬Û«H¥¦¤@¦¸ ²{¦b¬O®ÉÔ¤F¡AÅý¤j®a¬Ý¨ì004©M003ªº»ùȧa |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2021/2/2 ¤U¤È 06:42:12
²Ä 3593 ½g¦^À³
|
2019/10/31 ASLN ´£¥X¤F 1»õ¬üª÷¼W¸êªº¥Ó½Ð , 2019/12/5§¹¦¨¤F1500¸U¬üª÷ªºIPO ! 2021/01/29 ASLN ´£¥X¤F 1.5»õ¬üª÷¼W¸êªº¥Ó½Ð , ·|¤£·|¦³¥i¯à¤]¦b3¤ë©³«e§¹¦¨¸êª÷¶Ò¶°©O ? ¦pªG¼W¸êª÷ÃB¬O³Ì¤j¤Æ,ªÑ»ù´N¯uªº´N«Ü¤wÃzµo¤O¤F ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2021/2/2 ¤U¤È 05:50:10
²Ä 3592 ½g¦^À³
|
¬Q¤Ñ¨º¤@®Ú¬õ´Î13%¶qÁY¤ñ4¤Ñ«e20%Ãz¶qÁÙn°·±d ! ²z½×¤W¤µ¤ÑÀ³¸ÓÄòº¦¤~¹ï ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/2 ¤U¤È 03:24:31
²Ä 3591 ½g¦^À³
|
Ãèӧa¡A¦pªGªÑ»ù¯àæí½w¨B¦V¤W ´Á¤¤³ø§i¦n¼Æ¾Ú¬O¥i¥H´Á«Ýªº ¯un¤jº¦ÁÙ¬On¦n¼Æ¾Ú¥XÄl§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/2/2 ¤W¤È 09:25:06
²Ä 3590 ½g¦^À³
|
¬Q±ß¤S¬Oº}«Gªí²{¡A¦pªG¬ð¯}3¬ü¤¸¡A´N¬O°_¸ªº¶}©l!! ¹L¦~§¹¡A§â¦hªº¿ú¦A¥[½X......... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/2/2 ¤W¤È 08:33:45
²Ä 3589 ½g¦^À³
|
¦pªGasln ¯à¦³¤H¦b¬ü°êªºªÑ²¼ªÀ¸s¥¥x¨Ï¤§µo»Ã »¡¤£©w·|¦³¹³GameStop ªº¨«¶Õ tw.appledaily.com/property/20210201/CCMXAZ4ULRDDPPZEA35APVXB4Y/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/2 ¤W¤È 06:53:24
²Ä 3588 ½g¦^À³
|
Anaptys Bio¦b2018¦~2¤ëº¦¨ì³Ì°ª¡A¤½¶}¶Ò4»õ¬ü¤¸¡C
¨È狮ASAN004 ³Ì°ª»ùÈ¡A¦b¦Û°µ¤T´Á¡A¦Û¤v销°â¡A
¤è¯à¨É¨ü¡A À禬X2.5¿ªº¥«È¡C
¥¼¨ÓYÃÄ«~¤W¥«¦~Àøµ{»ù®æ ¥HDupilumab¥´64§é/¨C¤ë¤@°w¡C
ASLAN004¯uªº¦³¥i¯à100»õ¬ü¤¸ªºÀ禬预´Á¡C
100x2.5=250»õ¬ü¤¸¤§预´Á¡C
¤j约¤W¥«2¦~¥ª¥k¡AªÑ»ù¨£°ªÂI¡C
¦Ó¥¿±`¤W¥«3Ó¤ë¡A¥ý©Ô60x2.5=150»õ¬ü¤¸¥«È¬O¥i¯àªº¡C
n°µ3´ÁADÁ{§É3-5»õ¬ü¤¸¡A¶]¤£±¼¡C
«Ü¿N¿ú¡A¤jªÑªFY¤ä«ù¡A²z½×¤WªÑ»ù¥²©Ô°ª°ª¼W¸ê¡C
Y2b°µ§¹³Q¨ÖÁÊ¡A¶È40-45»õ¬ü¤¸ªº²b²{È¡C
¤@¤Á随缘¡I
¬ü°ê 1b ¤¤««× AD Á{§É ªÑ²¼, §ë¸ê´A¤O!
---------------------------------------------------- ASLAN004 24¦W,¤¤««× AD ·§©À©ÊÁ{§É¼Æ¾Úªº±N¤½¥¬ ¦P¯e¯f³Ì¨ÎASLAN004, ¬O§_¦³ AnaptysBio ,4-5Ó¤ë¡A ¤jº¦ 24»õ¬ü¤¸ªº¾÷·|? ¤@¦¸¤ÏÀ³ ?
----------------------------- AnaptysBio ,IL33 ªvÀø¤¤««×AD ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vµo¥¬12¦W·§©À©ÊÁ{§É¥¿¦V¼Æ¾Ú¡C
ªÑ»ù2017¦~10¤ë«Å¥¬«e32¬ü¤¸¡A³sº¦4-5Ó¤ë¡Aº¦¥|¿¡A³Ì°ª128¬ü¤¸¡A±q¥«È8»õ¬ü¤¸¡Aº¦¨ì32»õ¬ü¤¸¡C ------------------------------------
¥i±¤«e2Ó¤ë¡A2019¦~11¤ë8¤é¤½¥¬2b/300¤HADÁ{§É¸Ñª¼¥¼¹LÃö¡C ªÑ»ù¦^15¬ü¤¸¡A³Ñ¥|»õ¬ü¤¸¡C www.marketwatch.com/investing/stock/anab
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/2/1 ¤U¤È 01:35:11
²Ä 3587 ½g¦^À³
|
¤Ñ©R¤jºâ±o«Ü²M·¡ ©Ò¥H¤~»¡¶Ò1.5»õ¬ü¤¸§Æ±æ¤£¥u¬OÀH«K³Û³Û ¦pªG¯uªº¶Òªº¨ì ·Q¥²¤½¥q¤w¦³¬YºØµ{«×ªº§â´¤ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/1 ¤W¤È 11:23:33
²Ä 3586 ½g¦^À³
|
¬ü°ê 1b ¤¤««× AD Á{§É ªÑ²¼, §ë¸ê´A¤O!
---------------------------------------------------- ASLAN004 24¦W,¤¤««× AD ·§©À©ÊÁ{§É¼Æ¾Úªº±N¤½¥¬ ¦P¯e¯f³Ì¨ÎASLAN004, ¬O§_¦³ AnaptysBio ,4-5Ó¤ë¡A ¤jº¦ 24»õ¬ü¤¸ªº¾÷·|? ¤@¦¸¤ÏÀ³ ?
----------------------------- AnaptysBio ,IL33 ªvÀø¤¤««×AD ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vµo¥¬12¦W·§©À©ÊÁ{§É¥¿¦V¼Æ¾Ú¡C
ªÑ»ù2017¦~10¤ë«Å¥¬«e32¬ü¤¸¡A³sº¦4-5Ó¤ë¡Aº¦¥|¿¡A³Ì°ª128¬ü¤¸¡A±q¥«È8»õ¬ü¤¸¡Aº¦¨ì32»õ¬ü¤¸¡C ------------------------------------
¥i±¤«e2Ó¤ë¡A2019¦~11¤ë8¤é¤½¥¬2b/300¤HADÁ{§É¸Ñª¼¥¼¹LÃö¡C ªÑ»ù¦^15¬ü¤¸¡A³Ñ¥|»õ¬ü¤¸¡C www.marketwatch.com/investing/stock/anab
www.google.com.tw/amp/s/www.fool.com/amp/investing/2017/10/10/heres-why-anaptysbio-inc-is-rocketing-higher-today.aspx |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/2/1 ¤W¤È 11:13:21
²Ä 3585 ½g¦^À³
|
®Ú¾Ú¬ü°êªºªk«ß¡A¤p«¬ªÑ¨C¦¸¤½¶}¶Ò¸ê¤£¶W¹L¥«È1/3
n¶Ò1.5»õ¬ü¤¸
1.5»õ¬ü¤¸/(1/3)=4.5»õ¬ü¤¸¡X¡X¡X¥«È
¥h¦~©³ªÑ¥» ADR 190,000/5¡Ï3326=¬ù41326 ¤dªÑ
41326/3=13775 ¤dªÑADR¥i¶Ò
150,000,000¬ü¤¸/13775000ªÑ=10.9¬ü¤¸/ADR
¥H¤W¬O¦¨¥\¶Ò±o1.5»õ¬ü¤¸®É³Ì§C»ù®æ¡C
41326¡Ï13775=55,081¤dªÑADRªÑ¥» 55081x10.9=6»õ¬ü¤¸ªº¥«È
6/35
¶È¥Ø«e¨È·à±d¦X²z¥«È35»õ¬ü¤¸(Ó¤H¦ôp)ªº1/6¤£¨ì
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- YªÑ»ù¤jº¦¦Ü22¬ü¤¸½æ¥X¡A«h¥u»Ý13755/2=6877¤dªÑADR ,
41326¡Ï 6877=48203 ¤dªÑADR·sªÑ¥»
48,203X22=10.6»õ¬ü¤¸¥«È
¶È¥Ø«e¨È·à±d¦X²z¥«È35»õ¬ü¤¸ªº1/3¤£¨ì ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- Y¤jº¦¦Ü44¬ü¤¸½æ¥X¡A«h¥u»Ý13755/4=3438¤dªÑADR 41326¡Ï 3438=44764¤dªÑADR·sªÑ¥» 44764x44=19.7»õ¬ü¤¸
19.7/35=56% ¶È¥Ø«e¨È·à±d¦X²z¥«È35»õ¬ü¤¸ªº56%¤£¨ì ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X
¦UºØ¤è®×ªº¥i¯à¾÷²v¤£ª¾¡H»ù®æ·|©Ô¨ì¦ó³B¤£ª¾¡H ¬Ý¥«³õ¥D¤Oªº¥ø¹Ï¤ß
ASLAN004 AD MOA·§©À©ÊÁ{§É¹LÃö¡Aµ´¹ï¬O¤j¨Æ¡A ¬Û·í©ó¸~½F¤G´ÁÁ{§É¹LÃö¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/2/1 ¤W¤È 11:07:09
²Ä 3584 ½g¦^À³
|
¤W¦¸°O±o¬Ý¨ì¬üªÑ¤£¥i¼W¸ê¶W¹LªÑ¥» ªº¦Ê¤À¤ñ¦h¤Ö§Ñ°O¤F ¨º²{¦bn¶Ò¸ê¶W¹LªÑ¥»ªº¸êª÷¥i¥H¶Ü¡H |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 3001 ~ 3100 «h¦^ÂÐ >> |